Introduction {#s1}
============

The mitotic kinase AURKA controls centrosomal maturation, the timing of mitotic entry, bipolar and central spindle assembly, and cytokinesis ([@bib38]). AURKA is over-expressed in epithelial cancers, and it is believed to act as an oncogene through the induction of genomic instability. AURKA alters the number of centrosomes, the properties of the mitotic spindles, it induces aneuploidy and a defective cell division ([@bib7]; [@bib51]; [@bib38]). To perform these functions, AURKA interacts with multiple proteins at centrosomes and on the mitotic spindle, in a kinase-dependent or independent manner ([@bib38]). In mice, the over-expression of AURKA suffices to induce the appearance of mammary tumours similar to human breast cancers ([@bib47]; [@bib43]). Thus, AURKA has been of high interest for pharmaceutical companies as a drug target, despite the currently available drugs show only modest beneficial effects in patients. Although still at a preclinical level, the only promising strategy appears to be the combination of AURKA inhibitors with agents simultaneously targeting multiple cancer-relevant AURKA partners and functions ([@bib38]).

Epithelial cancers were found to be dependent on mitochondrial ATP, produced through oxidative phosphorylation, as a source of energy ([@bib49]). Particularly, epithelial cancer cells were found to carry a specific molecular signature constituted by 38 genes regulating the functionality of the mitochondrial respiratory chain, the synthesis of mitochondrial ribosomes and the import of proteins into mitochondria. It is known that mitochondria adapt their ATP production rate by modulating their morphology from fragmented organelles to an interconnected network ([@bib29]). In particular, mitochondrial fusion was shown to increase ATP production in several paradigms ([@bib30]; [@bib42]), granting protection against apoptosis ([@bib25]) and increasing cell proliferation ([@bib31]). However, how these effects are established by increasing mitochondrial connectivity remains to be mechanistically elucidated. In mammals, fusion is mediated by the Outer Mitochondrial Membrane GTPases MFN1 and 2 and the Inner Mitochondrial Membrane OPA1, which undergoes a proteolytic cleavage from a long (L-OPA1) to a short (S-OPA1) isoforms. The balance between L- and S-OPA1 is controlled by multiple mitochondrial proteases to ensure mitochondrial fusion both in normal and in stress conditions ([@bib29]). Conversely, mitochondrial fission is regulated by the cytosolic GTPase DNM1L through its interaction with several mitochondrial receptors (MFF, MIEF1 and 2, FIS1), but also through the regulation of its post-translational modifications (phosphorylation, SUMOylation, acetylation and S-nitrosilation) ([@bib29]). Mitochondrial fission is also used to separate dysfunctional mitochondria from the healthy network prior to their degradation by mitophagy, a selective type of autophagy ([@bib50]).

Given that AURKA is a hallmark of epithelial cancers, understanding the complexity of the AURKA interactome is mandatory to optimise therapeutic strategies in patients with epithelial cancers derived from AURKA over-expression. Despite often considered a mitotic protein, recent evidence showed that AURKA is active at interphase as well ([@bib34]; [@bib6]), although its roles beyond mitosis are still largely unexplored. We here show that interphasic AURKA localises to mitochondria, where it is imported and processed. While exploring the potential roles of mitochondrial AURKA, we observed that it increases mitochondrial fusion through a direct interaction with proteins regulating mitochondrial dynamics. The modulation of mitochondrial fusion and fission mechanisms when AURKA is over-expressed increases ATP production *via* the mitochondrial respiratory chain.

Results {#s2}
=======

AURKA localises in the mitochondrial matrix *via* an N-terminal MTS and it undergoes a double proteolytic cleavage {#s2-1}
------------------------------------------------------------------------------------------------------------------

While exploring the localisation of AURKA at interphase, we observed that AURKA co-localises with the mitochondrial processing peptidase PMPCB in human MCF7 cell lines ([Figure 1A](#fig1){ref-type="fig"}). The fluorescence signal of AURKA observed at mitochondria is specific, as it disappeared after AURKA knockdown by siRNA-mediated gene silencing ([Figure 1A](#fig1){ref-type="fig"} compare the two left panels and histograms). AURKA depletion also leads to profound changes in the organisation of the mitochondrial network, strongly suggesting a functional role of AURKA at mitochondria ([Figure 1A](#fig1){ref-type="fig"} compare the two middle panels). In addition, AURKA localises to mitochondria regardless of the cell cycle phase and of its relative abundance ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}).

![AURKA localises to mitochondria and it is imported into the mitochondrial matrix.\
(**A**) (Left) Immunofluorescence micrographs of MCF7 cells transfected with control (top panels) or AURKA-specific siRNA (bottom panels); cells were stained for endogenous AURKA (left panels) and with PMPCB (middle panels) for mitochondria. Inset: higher magnification of the dotted area. Scale bar: 10 µm. (Right) Mander's M1 and M2 co-localisation coefficients ([@bib8]) between AURKA and PMPCB on confocal pictures as in (**A**). n = 10 cells per condition; one representative experiment (of three) is shown. Whiskers extend from the 5th to the 95th percentiles. Outliers are indicated by white dots. (**B**) (Top) Lysates from total (**T**) and mitochondrial (**M**) fractions of HEK293 cells. Controls: TOMM70 (efficiency of mitochondrial isolation), TUBA1A (absence of cytosolic contaminations). (Bottom) Quantification of the abundance of each AURKA isoform in total or mitochondrial fractions. n = 3 independent experiments. (**C**) (Left) Intramitochondrial cleavage of endogenous AURKA in mitochondrial fractions of HEK293 cells transfected with control or PMPCB-specific siRNAs. (Right) Abundance of AURKA isoforms normalised against that of TOMM70 in control and PMPCB-depleted HEK293 cells. n = 3 independent experiments. (**D**) (Left) Localisation of ectopic AURKA-GFP in HEK293 cells by immunogold transmission electron microscopy (TEM) and (right) corresponding control condition without primary antibody. Table: number of gold beads per µm² of mitochondrial surface in the indicated mitochondrial subcompartments or non-mitochondrial cell surface (External). The relative abundance was then calculated by dividing the number of gold particles in each mitochondrial compartment by the number of 'External' particles. n = 20 images per condition from two independent experiments. Scale bar: 200 nm. (**E**) Isolation of mitochondrial soluble (S) and pellet (P) fractions by Na~2~CO~3~ extraction of mitochondrial fractions from HEK293 cells. Control cells were treated with NaCl. (**F**) Mitochondrial fractions from HEK293 cells digested with trypsin to degrade the OMM and blotted for endogenous AURKA. T = total lysate; ND = non digested mitochondrial fraction. To degrade the IMM and access the matrix, trypsin was combined with digitonin (+D) or Triton X-100 (+T). Controls for submitochondrial localisation: TOMM70 (OMM), CYCS (Inner Mitochondrial Space, IMS) and PMPCB (matrix). The submitochondrial compartments are indicated in the bottom part of the blot. AURKA~46~, AURKA~43~ and AURKA~38~ are indicated by blue, yellow and red flags, respectively. A.U.: arbitrary units. Data represent means ±s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 compared to the 'Control siRNA' condition (**A**), 'AURKA~46~' condition (**B and C**). *^a^P* \<0.01 and *^b^P* \<0.001 compared to the corresponding cleaved isoform in the 'Control siRNA' condition in (**C**). NS: not significant.](elife-38111-fig1){#fig1}

We then explored how AURKA is imported into mitochondria. The vast majority of mitochondrial proteins undergo one or sequential proteolytic cleavages when imported into these organelles ([@bib11]). First, the mitochondrial matrix peptidase PMPCB cuts the Mitochondrial Targeting Sequence (MTS) off the mitochondrial precursor protein ([@bib11]). Then, a second or multiple mitochondrial proteases can further cleave the pre-protein and allow it to reach the mitochondrial sub-compartment of destination. We therefore searched for mitochondrial AURKA isoforms representing one or more cleavage products. In immunoblots of total cell and mitochondrial lysates from HEK293 cells, AURKA could be detected as three isoforms: a predominant full-length isoform of \~46 kDa (AURKA~46~), an intermediate isoform of \~43 kDa (AURKA~43~) compatible with a first proteolytic cleavage by PMPCB ([@bib11]), and a short isoform of \~38 kDa (AURKA~38~) that presumably represents the mature mitochondrial isoform and which is detectable with a monoclonal ([Figure 1B](#fig1){ref-type="fig"}) and a polyclonal anti-AURKA antibody ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). These results also corroborate the mitochondrial localisation of AURKA in a second cell line. To confirm that AURKA~43~ and AURKA~38~ correspond to two AURKA isoforms processed inside mitochondria, we depleted 80% of the mitochondrial protease PMPCB. This almost completely blocked the intra-mitochondrial cleavage of AURKA ([Figure 1C](#fig1){ref-type="fig"}), strongly suggesting that AURKA~43~ and AURKA~38~ are mitochondrial cleavage products issued by PMPCB-related import pathways in the matrix. To identify the cleavage sites from where AURKA~43~ and AURKA~38~ originate we used nanoLC-ESI MS/MS to search for semi-tryptic peptides corresponding to the N-terminally processed isoforms AURKA~43~ and AURKA~38~. Compared to canonical peptides generated by the proteolytic action of trypsin, semi-tryptic peptides are cut non-canonically and they can therefore be generated by the action of mitochondrial proteases ([@bib45]). We retrieved two semi-tryptic peptides starting at residues 33 and between residues 80--82; the size of these peptides was consistent with the molecular weights of AURKA~43~ and AURKA~38~, respectively ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}).

We then investigated the exact sub-mitochondrial localisation of AURKA in HEK293 cells using transmission electron microscopy (TEM). We first detected ectopic AURKA fused to GFP in the mitochondrial matrix and in contact with mitochondrial *cristae* ([Figure 1D](#fig1){ref-type="fig"}). This localisation was confirmed by employing different antibody combinations ([Figure 1---figure supplement 1D and E](#fig1s1){ref-type="fig"}) and by illustrating that AURKA localises to the mitochondrial matrix similarly to the mitochondrial matrix protein SOD2 ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). To determine whether AURKA is a soluble protein or it is strongly attached to mitochondrial membranes, protein extraction with sodium carbonate was carried out on mitochondrial fractions of HEK293 cells ([Figure 1E](#fig1){ref-type="fig"}). AURKA was retrieved exclusively in the soluble fraction, reinforcing the conclusion that AURKA is mainly localised in the matrix as observed in TEM analyses. To further investigate the import of AURKA, we digested mitochondrial fractions of HEK293 cells with trypsin to eliminate mitochondrial protein precursors and peripheral Outer Mitochondrial Membrane (OMM) proteins, and we further combined trypsin with detergents to access the matrix. AURKA~38~ showed a degradation pattern similar to the one of the matrix PMPCB protease ([Figure 1F](#fig1){ref-type="fig"}). Together, these data demonstrate for the first time that AURKA is localised to mitochondria at interphase and that it is imported and processed in the mitochondrial matrix.

Positively charged motifs that are located at the amino termini of mitochondrial pre-proteins often target the pre-proteins to mitochondria ([@bib11]). Once there, pre-proteins interact primarily with the Translocase of Outer Mitochondrial Membrane (TOMM) complex, a multi-subunit machinery regulating the recognition and the entry of pre-proteins inside mitochondria ([@bib11]). Given that AURKA enters mitochondria and it is processed in the matrix, we analysed whether it follows a canonical import route through TOMM. In this light, we searched for the physical proximity of AURKA with the subunits of the TOMM machinery by FRET/FLIM ([@bib39]). Decreases in donor fluorescence lifetime in FRET/FLIM analyses indicated physical proximity compatible with protein-protein interactions between exogenously expressed AURKA and all the major TOMM subunits, TOMM 20, 22, 40 and 70 ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). We therefore searched the N-terminus of AURKA for a Mitochondrial Targeting Sequence (MTS) signature. The first 30 or 100 amino acids of AURKA fused to GFP were not detected in mitochondria by immunofluorescence microscopy, or in mitochondrial fractions of HEK293 cells subjected to western blotting ([Figure 1---figure supplement 2B and C](#fig1s2){ref-type="fig"}). This indicates that the N-terminal of AURKA is not sufficient to shuttle GFP to mitochondria and it suggests the absence of a canonical MTS in these regions of the protein. However, an AURKA truncation mutant in which the first 30 amino acids were removed (AURKA ΔNter) did not localise to mitochondria by confocal microscopy and western blotting ([Figure 1---figure supplement 3A and B](#fig1s3){ref-type="fig"}) and did not interact with TOMM ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}), although catalytically active in vitro towards two AURKA substrates, histone H3 and RALA ([@bib26]; [@bib22]; [@bib6]) ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). It has been described that AURKA is needed for RALA localisation to mitochondria, and that the two proteins participate in a common pathway to regulate mitochondrial fission at mitosis ([@bib22]). We therefore explored whether the import of AURKA inside mitochondria depends on the presence of RALA. We observed that the depletion of RALA does not inhibit the entry of AURKA into mitochondria. However, it impacts the abundance of AURKA to the same extent in total fractions and inside mitochondria. Therefore, the mitochondrial import of AURKA is RALA-independent ([Figure 1---figure supplement 3E](#fig1s3){ref-type="fig"}).

Intriguingly, AURKA~38~ was also detected in cytosolic fractions of HEK293 cells, indicating that the kinase is exported from mitochondria after processing ([Figure 2A](#fig2){ref-type="fig"}). To establish whether this feature is intrinsic to the AURKA MTS, we replaced the first 30 amino acids of AURKA with a well characterised, strong MTS derived from cytochrome *c* oxidase, which is known to be recognised by TOMM and cleaved by PMPCB ([@bib11]). This yields an exclusively mitochondrial AURKA (mitoAURKA), which was not exported back to the cytosol ([Figure 2B](#fig2){ref-type="fig"} and [Supplementary file 3C](#supp3){ref-type="supplementary-material"}). In addition, mitoAURKA did not localise at the centrosome when compared to normal AURKA ([Figure 2C](#fig2){ref-type="fig"}). The export of AURKA to the cytosol is further supported by the observation that ectopically expressed AURKA also shows abundant cytosolic staining ([Figure 2B and C](#fig2){ref-type="fig"} and [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), which could include the fraction of AURKA~38~ exported from mitochondria.

![AURKA is exported to the cytosol after intramitochondrial cleavage and it is active in the mitochondrion.\
(**A**) Representative western blot of the intramitochondrial cleavage of endogenous and 6xHis AURKA in total (T), mitochondrial (M) and cytosolic (C) fractions from HEK293 cells. (**B**) (Top) Confocal images of MCF7 cells transfected with AURKA-GFP or mitoAURKA-GFP. Mitochondria were stained with PMPCB. (Bottom left) Mander's M1 co-localisation coefficient between AURKA-GFP, AURKA ΔNter-GFP or mitoAURKA-GFP and PMPCB. *n* = 10 cells per condition from one representative experiment (of three). (Bottom right) Mitochondrial cleavage of mitoAURKA 6xHis cDNA in total (T), mitochondrial (M) and cytosolic (C) fractions from HEK293 cells. (**C**) Representative confocal images of MCF7 cells transfected as indicated. CETN1-iRFP670: centrosome marker. (**D**) (Left) Representative fluorescence (GFP channel) and lifetime images of MCF7 cells showing the mitochondrial localisation of GFP-AURKA or GFP-AURKA-mCherry expressed under the control of the minimal AURKA promoter ([@bib6]) and treated with DMSO or with the AURKA inhibitor MLN8237 (Alisertib). (Right) Corresponding ifetime quantifications. *n* = 10 cells per condition from one representative experiment (of three). Scale bar: 10 µm. (**E**) Representative western blot of mitochondrial fractions obtained from MCF7 cells expressing GFP-AURKA or GFP-AURKA-mCherry as in (**D**). (**F**) (Left) Abundance of AURKA and AURKA Lys162Met 6xHis cDNA and normalised to that of TOMM70 in total and mitochondrial fractions of HEK293; (right) corresponding quantification. AURKA was detected with an anti-His antibody. *n* = 3 independent experiments. Scale bar: 10 µm. AURKA~46~ and AURKA~38~ are indicated by blue and red flags, respectively. A.U.: arbitrary units. Data represent means ±s.e.m. \*p\<0.05, \*\*\*p\<0.001 compared to the compared to the 'AURKA-GFP' condition (**B**), the corresponding 'GFP-AURKA' condition (**D**) or to each 'Total AURKA' condition (**F**). NS: not significant.](elife-38111-fig2){#fig2}

Taken together, our data show for the first time that AURKA bears an atypical MTS that is necessary but not sufficient for its intracellular transport to and from mitochondria.

AURKA is enzymatically active at the mitochondria {#s2-2}
-------------------------------------------------

We next explored whether the kinase activity of AURKA is involved in its transport to, and function within, mitochondria. To this end, we used a previously published AURKA FRET biosensor, which allows to track the activation of AURKA *via* its autophosphorylation on Thr288 by FRET/FLIM ([@bib6]). The biosensor consists of a full-length AURKA carrying the donor FRET fluorophore EGFP at the N-terminus and the acceptor FRET fluorophore mCherry at the C-terminus, under the control of the minimal transcriptional regulatory region of AURKA to ensure the physiological expression of the kinase ([@bib6]). The AURKA biosensor localises at mitochondria as endogenous AURKA in MCF7 cells does ([Figure 2D,E](#fig2){ref-type="fig"} and see [Figure 1A](#fig1){ref-type="fig"} for comparison), and the decrease in the lifetime of GFP revealed that it is autophosphorylated on Thr288 and activated in mitochondria. This activation is abolished by the AURKA inhibitor Alisertib (MLN8237) ([Figure 2D](#fig2){ref-type="fig"}), an ATP-analogue currently under clinical trials ([@bib16]). Intriguingly, AURKA cleavage inside mitochondria is also supported by the presence of a double band in western blots from mitochondrial fractions of MCF7 cells expressing GFP-AURKA-mCherry ([Figure 2E](#fig2){ref-type="fig"}). In these fractions we detected a band at \~110 kDa and corresponding to the full GFP-AURKA-mCherry biosensor construct, and a second band at \~70 kDa potentially representing the cleaved (imported) biosensor without the GFP moiety.

Given that AURKA undergoes a two-step proteolytic cleavage when entering mitochondria, its activation is likely to occur prior to the cleavage of the MTS by PMPCB as this step removes the entire N-terminus, which comprises the MTS and the FRET donor. In this light, we assessed whether a kinase-dead mutant of AURKA (AURKA Lys162Met) could shuttle to mitochondria. Indeed, AURKA Lys162Met was not retrieved in mitochondrial fractions ([Figure 2F](#fig2){ref-type="fig"}), indicating that the kinase activity of AURKA is required for its mitochondrial localisation.

The enzymatic activity of AURKA at mitochondria suggests that the kinase might be involved in the regulation of mitochondrial functions. To understand the potential role played by AURKA at this compartment, we explored how the over-expression of the kinase may act on two interlinked mitochondrial functions: mitochondrial dynamics and energy production.

AURKA regulates mitochondrial morphology {#s2-3}
----------------------------------------

The mitochondrial dynamics balance has been shown to be crucial in cancer progression, as the mitochondrial network reshapes to meet the increasing energy requirements of cancer cells ([@bib44]; [@bib46]). As we detected a role of over-expressed AURKA in the control of mitochondrial energy production, we next evaluated whether AURKA plays a role in mitochondrial dynamics. First, we analysed mitochondrial morphology by TEM in HEK293 cells. Knockdown of AURKA led to mitochondrial elongation: the organelles appeared swollen, but they showed intact cristae and no apparent loss of intramitochondrial content ([Figure 3A](#fig3){ref-type="fig"}). Analyses of mitochondrial length and branching ([@bib24]) revealed that the silencing of AURKA increases the length of the whole mitochondrial network ([Figure 3---figure supplement 4A](#fig3s1){ref-type="fig"}), confirming previous results obtained with a kinase-dead version of AURKA ([@bib22]). Intriguingly, TEM analyses showed that mitochondria interconnectivity increases also when AURKA is over-expressed, again with no apparent signs of intramitochondrial content loss ([Figure 3A](#fig3){ref-type="fig"}). Under these conditions, analyses of mitochondrial network morphology showed that mitochondria are interconnected and they pack into mitochondrial clusters ([Figure 3---figure supplement 4A](#fig3s1){ref-type="fig"}).

![AURKA promotes mitochondrial fusion *in cellulo* and in vivo.\
(**A**) Mitochondrial ultrastructure of HEK293 cells by TEM transfected with control (first panel) or AURKA-specific (second panel) siRNAs, or with a cDNA encoding AURKA (third panel); quantification of mitochondrial length (fourth panel). *n* = 20 images per condition from two independent experiments. Scale bar: 200 nm. (**B**) MitoDendra2 photoconversion analysis for mitochondrial connectivity in wildtype (WT) flies, AURKA null (AurA ^ST/2G^) and gain-of-function (AurA ^O/E^) *Drosophila* mutants. Photoconversion area: dotted line. *n* = 80 images per condition from eight independent pupae obtained from three independent crossings. Scale bar: 5 µm. A.U.: arbitrary units. (**C**) Quantification of the abundance of the indicated mitochondrial fusion and fission proteins of total lysates of HEK293 cells transfected with control or AURKA-specific shRNAs. (**D**) Quantification of the indicated mitochondrial proteins from total lysates of HEK293 cells transfected with an empty vector, 6xHis AURKA or the indicated variants all fused to a 6xHis tag and blotted. n = 3 independent experiments. (**E**) FRET by FLIM analysis on MCF7 cells expressing AURKA-GFP together with DNM1L-mCherry, MFF-mCherry or with a mitochondrially-targeted mCherry (mitomCherry) used as a control. Mitochondria: dotted area. (Right panels). Pseudocolour scale: pixel-by-pixel lifetime. Scale bar: 10 µm. Data represent means ±s.e.m., \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 compared to the corresponding 'Control siRNA' condition (**A, C**), 'WT' genotype at 5 s after photoconversion (**B**), the 'Empty vector' condition (**D**) or 'AURKA-GFP/mitomCherry' donor-acceptor pair (**E**).](elife-38111-fig3){#fig3}

We then compared whether the degree of mitochondrial interconnectivity when AURKA is silenced or over-expressed. To this end, we used the diffusion of a photoconvertible Dendra2 targeted to the mitochondrial matrix (mitoDendra2). This fluorescent protein is photoconverted from green to red with a 405 nm laser, and the diffusion of the red species throughout the network is achieved only if mitochondria are organised in an electrochemical continuum. In parallel, we knocked-out AURKA in a multicellular organism as the fruit fly. In contrast to tumorigenic cells having heterogeneous genotypes and where the complete depletion of AURKA is not achievable, the fruit fly allows to compare the effects of the physiological abundance of AURKA on mitochondria to the ones observed after complete knock-out or overexpression of the kinase. In this model, we measured mitochondrial connectivity in the notum, a monolayer of epithelial cells that display three-dimensional and dynamic spatial organisation of the mitochondrial network. AURKA loss-of-function mutants or those harbouring an *AURKA*-targeted RNAi and gain-of-function mutants (overexpression of *Drosophila* AURKA) showed more interconnected mitochondria than did controls ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B and C](#fig3s1){ref-type="fig"}, red panels). By using the diffusion of red mitoDendra2, we confirmed that mitochondria are interconnected also in MCF7 cells both when AURKA is silenced or over-expressed ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}).We observed that mitochondrial interconnectivity in the presence of over-expressed AURKA depends on its capacity to be imported/exported, and on the kinase activity of AURKA itself, as the over-expression of AURKA ΔNter, mitoAURKA or the kinase-dead AURKA Lys162Met have no effect on mitochondrial elongation ([Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"}). Therefore, the role of AURKA in the regulation of mitochondrial morphology is conserved in flies and humans with no differences in mitochondrial connectivity due to the silencing or the overexpression of the kinase.

AURKA regulates mitochondrial fission in physiological conditions {#s2-4}
-----------------------------------------------------------------

Given that an increase in mitochondrial connectivity is observed both when AURKA is up- or downregulated, we sought to define the respective molecular mechanisms involved. We first analysed the abundance of the proteins involved in mitochondrial fusion and fission when AURKA was silenced or over-expressed. When AURKA was downregulated, the abundance of MFN1 and OPA1 increased while the level of DNM1L decreased ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). We then analysed the phosphorylation state of DNM1L on Ser637, since DNM1L localises in the cytosol when phosphorylated on this residue and to mitochondrial when dephosphorylated ([@bib22]; [@bib46]). Downregulation of *AURKA* lead to an increase of Ser637 phosphorylation, corresponding to an increased cytosolic localisation of DNM1L ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). Under these experimental conditions, increased mitochondrial connectivity at interphase could be reverted by normal AURKA expressed at physiological levels. On the contrary, the cytosolic-only AURKA ΔNter did not rescue mitochondrial elongation ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}), although this protein retains its catalytic activity and its capacity to phosphorylate RALA on Ser194 ([Figure 3---figure supplement 3D](#fig3s3){ref-type="fig"}).

The phosphorylation of DNM1L on Ser616 was previously shown to play an active role in promoting organelle fission at mitosis ([@bib22]). On the contrary, the phosphorylation of DNM1L on Ser637 observed at interphase and after silencing of AURKA indicates a lack of fission, which then results in increased mitochondrial connectivity. In physiological conditions, two distinct pathways appear to regulate mitochondrial fragmentation according to the cell cycle phase. At mitosis, fission mechanisms require translocation of RALA and its effector RALBP1 to the mitochondrion ([@bib22]), whereas this step is dispensable at interphase.

AURKA regulates mitochondrial fusion when over-expressed {#s2-5}
--------------------------------------------------------

When AURKA was over-expressed, we observed the increase of the short isoform of OPA1 (S-OPA1), a phenomenon previously reported to be directly caused by an increased mitochondrial respiratory chain activity ([@bib28]). In addition, we also observed a small but significant decrease of the levels of DNM1L and its receptor MFF ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3D](#fig3s3){ref-type="fig"}). Under these conditions, the phosphorylation of DNM1L on Ser637 remained globally unaltered ([Figure 3---figure supplement 3E](#fig3s3){ref-type="fig"}). While analysing mitochondria in tumorigenic cells, we observed that nearly 60% of cells with ectopic AURKA showed interconnected mitochondria clustered in the perinuclear region ([Figure 3---figure supplement 3F](#fig3s3){ref-type="fig"}). These structures are similar to insoluble mito-aggresomes, aggregates of mitochondria which cannot be degraded ([@bib13]). As mito-aggresomes, we found these AURKA-positive mitochondrial aggregates to be SDS-insoluble as indicated by dot-blot filter retardation assays ([Figure 3---figure supplement 3G](#fig3s3){ref-type="fig"}).

In vivo, the over-expression of the fly homologue of DNM1L -- Drp1 -- in flies over-expressing AURKA rescued mitochondrial interconnectivity analysed with mitoDendra2 ([Figure 3---figure supplement 3H](#fig3s3){ref-type="fig"}). Furthermore, we retrieved a direct interaction between AURKA, DNM1L and MFF by localised decrease of the lifetime of AURKA-GFP on mitochondria in FRET/FLIM analyses ([Figure 3E](#fig3){ref-type="fig"}). A similar decrease in GFP lifetime was not observed between over-expressed AURKA and the fusion protein MFN2 or the mitochondrial protein SNPJN2 not involved in mitochondrial dynamics ([Figure 3---figure supplement 3H](#fig3s3){ref-type="fig"}). This further corroborates the specificity of the interaction between AURKA, DNM1L and DMFF analysed by FRET/FLIM. Accordingly, the interaction between AURKA, DNM1L and MFF in the AURKA interactome was also detected by nanoLC-ESI MS/MS ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

Together, over-expressed AURKA directly interacts with the fission proteins DNM1L and MFF and drives mitochondrial elongation.

AURKA regulates mitochondrial morphology in cancer cells {#s2-6}
--------------------------------------------------------

To validate our data in a cancer cell context, we examined the morphology of the mitochondrial network and its correlation to the levels of AURKA expression in four breast cancer cell lines. Hs578T and MDA-MB-231 cells show low expression levels of AURKA, whereas MDA-MB-468 and T47D express AURKA at higher levels ([Figure 4A](#fig4){ref-type="fig"}). In all these cell lines, we also retrieved an AURKA-positive signal at mitochondria by immunoblotting. When looking at the morphology of the mitochondrial network, mitochondria appeared more fragmented in Hs578T and MDA-MB-231 cells, and more elongated in MDA-MB-468 and T47D ([Figure 4B](#fig4){ref-type="fig"}). To correlate this phenotype with the abundance of AURKA, we inhibited the kinase with MLN8237. MLN8237 had no effect on mitochondrial length in MDA-MB-468 and T47D cells, which express high levels of AURKA and where the mitochondrial network is already dramatically interconnected per se. Conversely, MLN8237 increased mitochondrial length and branching in Hs578T and MDA-MB-231 cells, where the abundance of AURKA is low and mitochondria appear fragmented in basal conditions ([Figure 4B](#fig4){ref-type="fig"}). This is consistent with what observed in MCF7 cells upon the depletion of *AURKA* by siRNA.

![AURKA regulates mitochondrial dynamics in four carcinoma cell lines.\
(**A**) Representative western blots (of three) of total and mitochondrial fractions from Hs578T, MDA-MB-231, MDA-MB-468 and T47D carcinoma cells, which were probed for endogenous AURKA, TOMM70 and TUBA1A. (**B**) Representative fluorescence micrographs and corresponding quantifications of mitochondrial length (aspect ratio) and branching (form factor), and illustrating the mitochondrial network morphology in each of the four cell lines used in (**A**). Mitochondria were stained with an anti-PMPCB antibody. Where indicated, cells were treated with 100 nM MLN8237 for 3 hr prior to fixation. Scale bar: 10 µm. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 for the indicated comparisons, *a* = *P* \< 0.05 compared to the corresponding 'DMSO' condition.](elife-38111-fig4){#fig4}

Together, AURKA plays two opposing functions in mitochondrial dynamics according to its abundance in the cell: contributing to organelle fission when expressed under physiological conditions, and directly increasing mitochondrial fusion when over-expressed. These roles of AURKA are conserved in four carcinoma cell lines, further increasing the relevance of these results.

Over-expressed AURKA increases the abundance of mitochondrial complex IV and up-regulates ATP production {#s2-7}
--------------------------------------------------------------------------------------------------------

We then analysed the mitochondrial energy capacity in HEK293 and MCF7 cells, in the presence and absence of over-expressed AURKA. We evaluated key parameters as the abundance of mitochondrial respiratory chain complexes, oxygen consumption for ATP production, the mitochondrial membrane potential and possible sources of mitochondrial stress as the activation of autophagy and of the Ubiquitin-Proteasome System (UPS). Among the levels of steady-state respiratory complexes, western blotting analysis revealed that the levels of the respiratory complex IV subunits increased in the presence of over-expressed AURKA ([Figure 5A](#fig5){ref-type="fig"}). It has been reported that increased abundance and activity of the respiratory complex IV are part of a mitochondrial-specific signature of epithelial cancers, which mainly rely on oxidative phosphorylation for ATP production ([@bib49]; [@bib44]). In this light, we observed that the oxygen consumption rate (OCR) -- a measure of mitochondrial respiration -- was increased when AURKA was over-expressed in HEK293 cells ([Figure 5B](#fig5){ref-type="fig"}) ([@bib49]; [@bib44]). Although only the steady-state levels of complex IV increased significantly in the presence of ectopic AURKA, the analysis of the interactome of AURKA by proteomics showed that AURKA directly interacts with multiple subunits of all respiratory complexes in HEK293 cells ([Supplementary file 2](#supp2){ref-type="supplementary-material"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This reinforces the conclusion that over-expressed AURKA globally acts on the mitochondrial respiratory chain to increase ATP production.

![Ectopic AURKA increases mitochondrial respiration together with the abundance and the functionality of the mitochondrial respiratory chain.\
(**A**) (Top) Western blot of total lysates of HEK293 cells transfected as indicated and (bottom) corresponding quantification of the relative abundances of the indicated oxidative phosphorylation complexes subunits, representing the abundance of the five oxidative phosphorylation complexes. *n* = 3 independent experiments. (**B**) Mitochondrial respiration of HEK293 cells over-expressing GFP or AURKA-GFP. *n* = 3 independent experiments. (**C**) Percentage of MCF7 cells over-expressing or silenced for AURKA and with activated MAP1LC3A-II and analysed by flow cytometry. *n* = 3 independent experiments. (**D**) Proteasomal activity in MCF7 cells transfected as indicated and analysed by flow cytometry. *n* = 3 independent experiments. RFU: relative fluorescence units. (**E**) MitoTimer red/green ratio in MCF7 cells transfected as indicated. *n* = 3 independent experiments. (**F**) Red fluorescence of the mitochondrial potentiometric probe JC-1 in MCF7 cells transfected as indicated and analysed by flow cytometry. The decrease in red JC-1 fluorescence provides a readout of ΔΨloss. *n* = 3 independent experiments. (**G**) TMRM relative fluorescence of MCF7 cells transfected as indicated and treated with DMSO (basal conditions) or carbonyl cyanide m-chlorophenyl hydrazone (CCCP). *n* = 3 independent experiments. (**H**) Mitochondrial respiration of HEK293 cells over-expressing a control or an *AURKA*-specific shRNA. *n* = 3 independent experiments. (**I**) Percentage of live, apoptotic and dead MCF7 cells analysed by flow cytometry and identified by the incorporation of Annexin V. *n* = 3 independent experiments. (**L**) Mitochondrial respiration of HEK293 cells treated with DMSO or MLN8237 at a concentration of 100 nM for 3 hr or of 250 nM for 10 min. *n* = 3 independent experiments. (**M**) Cartoon diagram of AURKA silencing or overproduction acting differentially on key mitochondrial functions. Green arrows: upregulation; red arrows: downregulation. UPS: ubiquitin-proteasome system; CIV: mitochondrial complex IV. Data represent means ±s.e.m. \*\*\*p\<0.001 compared to each corresponding 'Control shRNA' condition, (**A, C--F**), the 'GFP' condition (**B**), each 'basal' condition (**G**), or to each corresponding 'Control siRNA' condition (**H--I**). *^a^P* \<0.01 compared to the corresponding 'Control siRNA' condition for each treatment (**G**). All comparisons in (**L**) were not significant.](elife-38111-fig5){#fig5}

We then analysed mitochondria-related stress levels in the presence and absence of AURKA by flow cytometry. The over-expression of AURKA increased the proportion of cells exhibiting ongoing autophagy ([Figure 5C](#fig5){ref-type="fig"}). On the contrary, the downregulation of AURKA increased the activity of the ubiquitin-proteasome system ([Figure 5D](#fig5){ref-type="fig"}), which has been proposed to be a complementary system of autophagy for the degradation of selective mitochondrial proteins ([@bib53]). To specifically evaluate the turnover of mitochondria, we calculated the red/green ratio of MitoTimer ([@bib14]). Increasing levels of red mitoTimer were observed in cells transfected with an AURKA-shRNA ([Figure 5E](#fig5){ref-type="fig"}), indicating that mitochondrial turnover was attenuated under these conditions. The increased red mitoTimer was specifically due to mitochondrial turnover, as we did not detect significant reactive oxygen species variations when downregulating or over-expressing AURKA (Data not shown). Mitochondrial membrane potential (ΔΨ) -- another indicator of mitochondrial functionality -- measured with JC-1 ([Figure 5F](#fig5){ref-type="fig"}) or with Tetramethylrhodamine Methyl Ester (TMRM) ([Figure 5G](#fig5){ref-type="fig"}) decreased upon AURKA knockdown, further confirming that mitochondria are defective in the absence of AURKA. Although mitochondria are depolarised after AURKA knockdown, no global effect on the mitochondrial oxygen consumption rate was observed under these conditions ([Figure 5H](#fig5){ref-type="fig"}), despite both AURKA knockdown and over-expression have an impact on cell viability as previously published ([Figure 5I](#fig5){ref-type="fig"}) ([@bib51]; [@bib3]). In addition, the mitochondrial ATP production did not differ from that of control cells when AURKA was inhibited with MLN8237, corroborating the finding that both silencing and inhibition of AURKA do not alter mitochondrial ATP production ([Figure 5L](#fig5){ref-type="fig"}).

In conclusion, our results indicate that AURKA maintains mitochondrial fission when expressed at physiological levels and that mitochondrial interconnectivity in the absence of AURKA is a consequence of a lack of fission. This results in the mere accumulation of elongated mitochondria without any increase in the energetic capabilities of the mitochondrial network. On the contrary, over-expressed AURKA actively enhances ATP production by promoting mitochondrial interconnectivity. These data reveal a novel role of AURKA in the control of mitochondrial bioenergetics, by acting on the mitochondrial respiratory chain and on mitochondrial functionality ([Figure 5M](#fig5){ref-type="fig"}).

Discussion {#s3}
==========

Over-expression of AURKA is observed in many epithelial cancers. Increased copy number of the AURKA gene region is generally associated with an aggressive disease and poor patient survival. The AURKA gene region is located on chromosome 20, and its amplification includes the enhanced expression of additional genes (e.g. genes regulating cell cycle progression, and the most well-described AURKA interactor TPX2) ([@bib4]; [@bib40]). In addition, the overexpression of AURKA has been linked with chromosomal instability ([@bib2]). These events are common in different cancer types as in ovarian, pancreatic, lung and colon cancers and lead to bad prognosis. For instance, the increased copy number of AURKA is associated with the evolution of colorectal polyp into carcinoma ([@bib10]). In breast cancer, the overexpression of AURKA is also linked to poor survival and it is associated with the overexpression of the human growth factor receptor 2 (HER2) and progesterone receptor ([@bib35]). Although epithelial cancers are non-glycolytic tumours and use the OXPHOS chain to produce ATP ([@bib49]), none of the above-mentioned studies took into account mitochondrial dysfunctions caused by or appearing in the presence overexpressed AURKA. Our study is thus pioneer in correlating for the first time this multifaceted kinase and mitochondrial physiology.

In addition to its well-characterised roles in mitosis, new functions of AURKA during interphase are regularly discovered ([@bib34]; [@bib6]; [@bib52]). We here demonstrated that AURKA is imported in the mitochondrial matrix. To reach this compartment, AURKA physically interacts with the TOMM complex, the major entry gate for mitochondrial proteins. Once it enters mitochondria, AURKA is cleaved in a two-step process to become a fully mature mitochondrial protein, potentially capable of interacting with multiple mitochondrial partners as the mitochondrial respiratory chain subunits. We discovered that the signal required for the import of AURKA into mitochondria is located within the first 36 amino acids of the kinase. Conventionally, MTS are incapable of shuttling to mitochondria when fused at the C-terminus of a fluorophore ([@bib11]). AURKA MTS is indeed atypical, as its mitochondrial import is not blocked by the presence of a GFP at its N-terminus. In addition, the inability of this MTS to shuttle a generic GFP to mitochondria further suggest that the AURKA MTS may belong to a new class of weak mitochondrial targeting signals ([@bib27]), previously reported to require a specific folding conformation or post-translational modification to shuttle to mitochondria ([@bib21]). The hypothesis that centrosomal proteins play additional roles at mitochondria has already been raised ([@bib33]). It has been shown that the mitochondrial protein SUCLA2, which catalyses the conversion of succinyl CoA into succinate inside mitochondria, has a mitochondrial and centrosomal double localisation in *Drosophila* ([@bib20]). It was shown that centrosomal SUCLA2 regulates the number and the stability of centrosomes, and this raises the fascinating hypothesis that mitochondrial proteins could in turn play roles at the centrosome under certain conditions (e.g. the cell cycle phase). Given that AURKA is preferentially a centrosomal protein now shown to directly regulate mitochondrial functions, it is tempting to speculate that this mitochondria-to-centrosome crosstalk could also work in a retrograde manner from the centrosome to mitochondria, with centrosomal proteins as AURKA also regulating mitochondrial functions. In this light, it will be interesting to explore whether the centrosomal and mitochondrial pools of AURKA are spatiotemporally connected. To this end, further studies are required to establish the exact molecular mechanisms that allow the first 36 amino acids of AURKA to act as a MTS only when bound to the rest of the protein.

We then searched for potential roles of AURKA at mitochondria and for impairments of mitochondrial functionality when AURKA is over-expressed. We discovered that the over-expression of AURKA enhances mitochondrial ATP production. In exploring the mitochondrial interactome of AURKA during interphase, we discovered that one out of five interactors of AURKA is a mitochondrial protein as revealed by nanoLC-ESI MS/MS analyses ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Proteins regulating energy metabolism in the cell, including multiple subunits of the mitochondrial respiratory chain, were found to significantly interact with AURKA at interphase ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This strongly supports a role of AURKA in the control of the mitochondrial respiratory chain functionality.

It is known that an interconnected mitochondrial network favours ATP production through mixing of the intramitochondrial content, which also counteracts the effects of deleterious mtDNA mutations in vivo ([@bib36]). Interconnected mitochondrial networks have been proposed to act as energy-transmitting cables, delivering energy to parts of the cell in which oxygen for mitochondrial respiration is low ([@bib48]). Mitochondrial fusion is also stimulated in selected stress conditions as starvation, helping the cell to cope with increasing energy demands ([@bib42]). The over-expression of AURKA represents a mitotic stress paradigm with centrosome abnormalities, chromosome misalignment, aberrant DNA inheritance at cell division and apoptosis ([@bib51]; [@bib38]). Therefore, it is not surprising that mitochondria under these conditions modify their functionality beyond mitosis as well, adapting to stress by increasing their connectivity and the production of ATP during interphase. On the contrary, the increased mitochondrial connectivity observed in the absence of AURKA or when the kinase is pharmacologically inhibited does not lead to an increased ATP production. However, the connectivity of the mitochondrial network under these conditions resembles the one observed when AURKA is overexpressed. As AURKA drives mitochondrial fission when expressed at physiological levels, the absence of AURKA or the inhibition of its catalytic activity lead to the appearance of interconnected mitochondrial networks. In the absence of an active AURKA, the paradigms regulating mitochondrial fission are therefore limited and fusion remains the only mechanism left to regulate mitochondrial morphology, as previously proposed in conditions of fission inhibition ([@bib17]). In this light, we indeed demonstrate that the molecular mechanisms used by AURKA to regulate mitochondrial dynamics are distinct according to the expression levels of the kinase. When AURKA is silenced, fission is inhibited. In conditions where AURKA is overexpressed, fusion is enhanced and so is the energetic capability of the entire mitochondrial network. In conclusion, the modifications induced by AURKA to mitochondrial morphology are multifaceted and, in this context, the simple interconnectivity of the mitochondrial network is not a direct readout of the energetic capabilities of mitochondria.

The AURKA interactome and FRET by FLIM analyses show that AURKA directly interacts with DNM1L and MFF. A direct interaction of cytosolic AURKA with proteins regulating mitochondrial dynamics is conceivable, as they are mainly located on the OMM. Nevertheless, the physical interaction of the kinase with multiple components of the mitochondrial respiratory chain, located on the Inner Mitochondrial Membrane, would require the kinase to be imported into mitochondria to ultimately promote ATP production. This is also in agreement with an increased abundance of the Inner Mitochondrial Membrane protein S-OPA1 induced by AURKA overexpression. Of note, increased S-OPA1 is a previously characterised hallmark of augmented mitochondrial respiratory chain activity ([@bib28]), which further reinforces our conclusion that over-expressed AURKA directly potentiates the functionality of the mitochondrial respiratory chain. However, further studies are required to understand how AURKA spatiotemporally interacts with its multiple partners and if different sub-mitochondrial pools of AURKA are capable of driving changes in mitochondrial morphology and in energy production.

Recent findings showed that mitotic AURKA promotes mitochondrial fission through the phosphorylation of RALA on Ser194 in the cytosol ([@bib22]). Through this modification, RALA can shuttle to mitochondria to ensure the correct segregation of these organelles to daughter cells. We therefore sought to understand whether the role played by AURKA at mitochondria during interphase falls within the interplay between AURKA and RALA. First, the kinase is imported into mitochondria regardless of RALA. Second, the MTS of AURKA is the only portion of the protein strictly required for the pro-fission role of AURKA in physiological conditions. Indeed, a version of AURKA devoid of this fragment is unable to induce organelle fragmentation although it is fully capable of phosphorylating RALA on Ser194. Therefore, our study demonstrates that AURKA can impact on mitochondrial functions following two parallel pathways: a RALA-independent pathway during interphase, and by interacting with RALA at mitosis ([@bib22]). Although we demonstrated the existence of two different pathways taken by AURKA, further studies are necessary to better characterise their molecular players and their potential interplay.

In conclusion, we propose the mitochondrial pool of AURKA regulates the fusion of interconnected organelles and, by doing so, it controls ATP production ([Figure 6](#fig6){ref-type="fig"}). Mitochondria with high metabolic capacity might escape turnover through fusion mechanisms and thus sustain the high metabolic needs of cancer cells, potentially representing a selective advantage for epithelial cancer progression. Targeting mitochondrial hyperfunctionality together with AURKA inhibition might therefore represent an innovative approach in the development of anti-cancer treatments.

![AURKA induces mitochondrial hyperfusion *via* its import/export cycle to enhance mitochondrial ATP production.\
(1-3) Timeline and corresponding representation of the import of AURKA via TOMM, the first proteolytic cleavage of AURKA inside the mitochondrial matrix by the PMPCB protease and the second proteolytic cleavage by a still unknown protease. Subsequent mechanisms leading to the export of AURKA in the cytosol after mitochondrial cleavage remain to be elucidated. (4) Exported AURKA induces the fusion of remaining mitochondria in an interconnected network. AURKA-dependent mitochondrial fusion leads to increased ATP levels.](elife-38111-fig6){#fig6}

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                 Source or reference         Identifiers               Additional information
  or resource                                                                                                 
  ------------------------- --------------------------- --------------------------- ------------------------- ------------------------------------------
  Genetic reagent\          WT (w^1118^)                NA                          NA                        
  (*D. melanogaster*)                                                                                         

  Genetic reagent\          Sca-Gal4                    PMID: 2125959               NA                        
  (*D. melanogaster*)                                                                                         

  Genetic reagent\          mitoDendra2                 Dr. Thomas Rival\           NA                        
  (*D. melanogaster*)                                   (University of Marseille)                             

  Genetic reagent\          *aurA ST*                   PMID: 23685146              NA                        
  (*D. melanogaster*)                                                                                         

  Genetic reagent\          *aurA 3A*                   this paper                  NA                        *aurA^3A^* indel
  (*D. melanogaster*)                                                                                         

  Genetic reagent\          *aurA 2G*                   this paper                  NA                        *aurA^2G^* indel
  (*D. melanogaster*)                                                                                         

  Genetic reagent\          *aurA dsRNA*                Vienna Drosophila\          VDRC: 108446              
  (*D. melanogaster*)                                   RNAi Center                                           

  Genetic reagent\          *aurA exel*                 Bloomington Drosophila\     BDSC: 8376                
  (*D. melanogaster*)                                   Stock Center                                          

  Genetic reagent\          *aurA exel*                 Bloomington Drosophila\     BDSC: 8377                
  (*D. melanogaster*)                                   Stock Center                                          

  Genetic reagent\          *Drp1*                      Bloomington Drosophila\     BDSC: 51647               
  (*D. melanogaster*)                                   Stock Center                                          

  Cell line (H. sapiens)    MCF7                        ATCC                        HTB-22                    Maintained in DMEM supplemented with\
                                                                                                              10% FBS, 1% penicillin/streptomycin and\
                                                                                                              1% L-Glutamine

  Cell line (H. sapiens)    HEK293                      ATCC                        CRL-1573                  Maintained in DMEM supplemented with\
                                                                                                              10% FBS, 1% penicillin/streptomycin and\
                                                                                                              1% L-Glutamine

  Cell line (H. sapiens)    Hs578T                      ATCC                        HTB-126                   Maintained in the Legembre Lab in DMEM\
                                                                                                              supplemented with 10% FBS, 1%\
                                                                                                              penicillin/streptomycin and 1% L-\
                                                                                                              Glutamine

  Cell line (H. sapiens)    MDA-MB-231                  ATCC                        HTB-26                    Maintained in the Legembre Lab in DMEM\
                                                                                                              supplemented with 10% FBS, 1%\
                                                                                                              penicillin/streptomycin and 1% L-\
                                                                                                              Glutamine

  Cell line (H. sapiens)    MDA-MB-468                  ATCC                        HTB-132                   Maintained in the Legembre Lab in DMEM\
                                                                                                              supplemented with 10% FBS, 1%\
                                                                                                              penicillin/streptomycin and 1% L-\
                                                                                                              Glutamine

  Cell line (H. sapiens)    T47D                        ATCC                        HTB-133                   Maintained in the Legembre Lab in DMEM\
                                                                                                              supplemented with 10% FBS, 1%\
                                                                                                              penicillin/streptomycin and 1% L-\
                                                                                                              Glutamine

  Antibody                  AURKA                       Merck Millipore             PC742                     1:1000

  Antibody                  AURKA                       home made                   clone 5C3\                1:20
                                                                                    (ref. 48 of this paper)   

  Antibody                  Drp1                        BD Pharmingen               611112                    1:2000

  Antibody                  Drp1 pS616 (DA91)           Cell Signaling              4494                      1:1000

  Antibody                  Drp1 pS637                  Cell Signaling              4867                      1:1000

  Antibody                  Fis1 (TTC1) clone EPR8412   abcam                       ab156865                  1:1000

  Antibody                  GFP                         Roche/Sigma Aldrich         11814460001               1:1000

  Antibody                  Histone H3 pS10             Millipore                   06--570                   1:10,000

  Antibody                  His tag                     Covalab                     mab90001-P                1:3000 in 3% BSA

  Antibody                  Mff                         abcam                       ab81127                   1:500

  Antibody                  MitoFusin 1                 abcam                       ab57602                   1:1000

  Antibody                  MitoFusin 2                 abcam                       ab56889                   1:500

  Antibody                  Opa1                        abcam                       ab157457                  1:1000

  Antibody                  OXPHOS Rodent WB\           Mitosciences                ab110413                  1:1000
                            Antibody Cocktail                                                                 

  Antibody                  PMPCB                       Proteintech                 16064--1-AP               1:1000

  Antibody                  RalA S194                   Millipore                   07--2119                  1:1000

  Antibody                  Tom22                       Abcam                       ab10436                   1:500

  Antibody                  Tom70                       Abcam                       ab106193                  1:5000

  Antibody                  Tubulin alpha clone YL1/2   Millipore                   MAB1864                   1:5000

  Antibody                  VDAC1                       Abcam                       ab15895                   1:1000

  Chemical compound, drug   MLN8237/Alisertib           Selleck chemicals           S1133                     

  Chemical compound, drug   TMRM                        Thermo Fischer scientific   T668                      

  Sequence-based reagent    Allstar Control siRNA       Qiagen                      SI03650318                

  Sequence-based reagent    AURKA siRNA                 Eurogentec                  NA                        sequence 5\'-AUGCCCUG\
                                                                                                              UCUUACUGUCA-3\'

  Sequence-based reagent    RALA siRNA                  Qiagen                      SI03650318                

  Sequence-based reagent    PMPCB siRNA                 Dharmacon                   L-004747- 00--0005        

  Recombinant DNA reagent   AURKA shRNA                 Sigma Aldrich               SHCLNG-NM_003600          

  Recombinant DNA reagent   Control shRNA               Sigma Aldrich               SHC002                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Expression vectors and molecular cloning {#s4-1}
----------------------------------------

Unless purchased from Addgene, DNA constructs were generated using Gibson Assembly Master Mix (New England Biolabs) and T4 DNA ligase (Thermo Fisher Scientific). All restriction enzymes were purchased from Thermo Fisher Scientific. All cloning reactions were verified on a 3130 XL sequencer (Applied Biosystems). All site-directed mutagenesis reactions were performed by QuickChange site-directed mutagenesis (Stratagene). Vectors carrying AURKA ΔNter were constructed by removing the first 30 aminoacids of AURKA; mitoAURKA was constructed by adding the MTS of cytochrome *c* oxidase to AURKA ΔNter. The complete list of plasmid used in the study is reported in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

Cell culture reagents {#s4-2}
---------------------

Mycoplasma-free MCF7 (HTB-22) and HEK293 (CRL-1573), cells were purchased from the American Type Culture Collection and grown in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 10% foetal bovine serum (GE Healthcare), 1% L-glutamine (GE Healthcare) and 1% penicillin--streptomycin (GE Healthcare). Hs578T, MDA-MB-231, MDA-MB-468 and T47D cells were a kind gift of P. Legembre (CLCC Eugène Marquis, Rennes) and were grown in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 10% foetal bovine serum (GE Healthcare), 1% L-glutamine (GE Healthcare) and 1% penicillin--streptomycin (GE Healthcare). For live microscopy experiments, cells were incubated in phenol red-free Leibovitz's L-15 medium (Thermo Fisher Scientific) supplemented with 20% foetal bovine serum, 1% L-glutamine and 1% penicillin--streptomycin. All live microscopy experiments were performed at 37°C in Nunc Lab-Tek II Chamber slides (Thermo Fisher Scientific). Validated siRNA against PMPCB was purchased from Dharmacon (L-004747- 00--0005), AllStars negative control (SI03650318) and validated siRNA against RALA (SI02662835) were purchased from Qiagen; the siRNA against AURKA was synthesised as previously described ([@bib6]) (sequence: 5'-AUGCCCUGUCUUACUGUCA-3') and purchased from Eurogentec. The *AURKA*-specific (SHCLNG-NM_003600) and non-targeting control (SHC002) shRNAs were purchased from Sigma-Aldrich. Plasmids, siRNAs and shRNAs were transfected by the calcium phosphate method or with Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. Cells were plated at 70% confluence in 96-well cell plates for plate reads, in 24-well cell plates for immunocytochemistry, or on 10 or 15 cm^2^ petri dishes for total cell lysates and subcellular fractionation. Cells were harvested, fixed or imaged 48 hr after transfection unless otherwise indicated. MLN8237/Alisertib was purchased from Selleck Chemicals and used at a final concentration of 250 nM for 10 min or of 100 nM for 3 hr before imaging, cell fixation or harvesting. Tetramethylrhodamine methyl ester perchlorate (TMRM, Thermo Fisher Scientific, 50 nM) was incubated with the cells for 30 min at 37°C in phenol-free medium before imaging.

Generation of AurA knockout *Drosophila* strains {#s4-3}
------------------------------------------------

*AurA^2G^* and *aurA^3A^* indels were generated using the approach described in ([@bib23]). Briefly, gRNAs targeting exon 2 (GGCGCTTTGATCAGGAAGCCAGG) or exon 3 (GGAAAAGGAATCCCAGTTCGTGG) of AurA were cloned into the pBFv-U6.2 vector. Following molecular validation by sequencing, the pBFv-U6.2. exon2 gRNA or pBFv-U6.2. exon3 gRNA plasmids were injected into *y^1^ v^1^* P{nos-PhiC31C\\int.NLS}X; P{caryP}attP40 (stock BDSC25709) by Rainbow Transgenic Flies, Inc. The resulting male transformants *y^1^ v^1^* P{nos-PhiC31C\\int.NLS}X; P{U6.2-exon2 (or exon 3)gRNA} attP40 were balanced over CyO using *y^2^ cho^2^ v^1^; Sp/CyO* stock. Male *y^2^ cho^2^ v^1^*; P{U6.2-exon2 (or exon 3)gRNA}attP40/CyO flies were next crossed with female *y^2^ cho^2^ v^1^*; P{nos-cas9}attP40/CyO flies. The resulting male *y^2^ cho^2^ v^1^*; P{nos-cas9}attP40/P{U6.2-exon2 (or exon 3)gRNA}attP40; *aurA ^(indel\ ?)^* flies were crossed with *w; kr^If^*/CyO; MKRS/TM6, Tb, Hu females. Single males of the genotype *w*; P{nos-cas9}attP40/CyO; *AurA ^(indel\ ?)^*/TM6, Tb, Hu were crossed with *w; kr^If^*/CyO; MKRS/TM6, Tb, Hu females. The resulting *w; r^If^*/CyO; *AurA ^(indel\ ?)^*/TM6, Tb, Hu stock was established and characterised by sequencing. *AurA^2G^* is a 17 bp deletion that induces a frame-shift and eventually a STOP codon, encoding a 100-aa protein containing the first 61 aa of AurA. *AurA^3A^* is a 7 bp deletion encoding a 180-aa protein containing the first 177 aa of AurA. Both alleles fail to complement *aurA^ST^* null allele ([@bib32]), and no AurA protein was detected by western blot. UAS-mitoDendra2 flies were established by adding the cytochrome *c* oxidase MTS to the Dendra2 fluorophore. The remaining strains used in this study are listed in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. *Drosophila melanogaster* crossings were set up and grown at 25°C. All crossings and the corresponding Fig. panels are listed in [Supplementary file 5](#supp5){ref-type="supplementary-material"}; *w^1118^* pupae were used as wild-type controls for all experiments. Pupae were collected as white pupae, aged for 16 hr at 25°C and mounted on glass slides prior to imaging. All images collected in this study were acquired from epithelial cells of the dorsal thorax (notum) at room temperature.

Mitochondrial isolation, sodium carbonate extraction, trypsin digestion and in vitro kinase assays {#s4-4}
--------------------------------------------------------------------------------------------------

Total protein fractions were obtained by lysing cells in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1.5 mM MgCl~2~, 1% Triton X-100, and 0.5 mM dithiothreitol (DTT) supplemented with 0.2 mM Na~3~VO~4~, 4 mg/ml NaF, 5.4 mg/ml β-glycerophosphate and protease inhibitors (Complete Cocktail, Roche) followed by centrifugation at 13,000 *g* for 20 min at 4°C. Isolated mitochondrial fractions were obtained by differential centrifugation as previously described ([@bib5]) and were digested with 1 μg of trypsin (Sigma-Aldrich) per 10 µg of protein at 37°C for the indicated incubation times ([Figure 1F](#fig1){ref-type="fig"}). Digestion of the inner mitochondrial membrane was performed by adding 2 µg/µl digitonin or 3% Triton X-100 to trypsin-digested fractions. Insoluble/soluble mitochondrial protein fractions were obtained by alkaline extraction. Briefly, mitochondrial fractions were incubated on ice with 200 mM Na~2~CO~3~ or NaCl as a control followed by incubation of the pellet and soluble fractions in 600 mM sorbitol (Sigma-Aldrich) and 20 mM HEPES-KOH (Sigma-Aldrich, pH 7.4). Proteins were precipitated in 12% trichloroacetic acid (Sigma-Aldrich), washed three times with acetone, dried and resuspended in Laemmli sample buffer. Cytosolic fractions were obtained from mitochondria-free protein fractions using Amicon Ultra 4 ml filters for protein purification and concentration (10 kDa cutoff, Merck Millipore) according to the manufacturer's instructions. Protein purification and in vitro kinase assays were performed as described in ([@bib6]).

Western blotting analyses and dot-blot filter retardation assay {#s4-5}
---------------------------------------------------------------

All protein fractions were assayed using the Bradford reagent (Bio-Rad) and then boiled in Laemmli sample buffer, resolved by SDS--PAGE, transferred onto a nitrocellulose membrane (GE Healthcare) and analysed by western blotting. Dot-blot filter retardation assays were performed in a 96-well BioDot microfiltration unit (Bio-Rad) using a 0.22 µm cellulose acetate membrane (Dutscher). After treatment, the samples were resuspended in 2% SDS, loaded onto the membrane, filtered and washed twice with 0.1% SDS. The list of primary antibodies is in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. Secondary horseradish-peroxidase-conjugated antibodies (anti-mouse and anti-rabbit) were purchased from Jackson ImmunoResearch Laboratories; anti-rat antibodies were purchased from Bethyl Laboratories. The membranes were incubated with commercially available (Pierce) or homemade enhanced chemiluminescence substrate as described in ([@bib6]). Chemiluminescence signals were captured on film (CP-BU new, Agfa Healthcare), developed using CURIX 60 developer (Agfa Healthcare) and quantified with ImageJ software (NIH). The relative abundance of specific bands of interest was calculated by normalising it towards the abundance of loading controls and indicated in each graph.

Oxygen consumption rate measurements {#s4-6}
------------------------------------

Cells were trypsinised, resuspended in growth medium, and placed in the respiratory chamber of an Oroboros Oxygraph-2k (WGT). Cellular respiration was determined under basal conditions in the presence of oligomycin (1 µg/ml, Sigma-Aldrich) to estimate leakage and/or in the presence of increasing amounts (2.5--5 µM) of CCCP (Sigma-Aldrich) to obtain maximal respiration. The respiration reserve capacity was calculated by subtracting the basal respiration from the maximal respiration. The mitochondrial respiratory control corresponded to the basal/leak ratio. 'ATP' indicates the O~2~ consumption used for ATP synthesis. Mitochondrial respiration was inhibited by the addition of 1 mM potassium cyanide (KCN, Sigma-Aldrich).

Mass spectrometry {#s4-7}
-----------------

AURKA-GFP isolated by affinity-purification in whole cell extracts or mitochondrial fractions were resolved by SDS-PAGE using 4--12% Criterion XT Bis-Tris gradient gel (Bio-Rad) and stained with Sypro Ruby (Bio-Rad). Bands corresponding to AURKA~46~, AURKA~43~ and AURKA~38~ were extracted from gels and processed for in-gel digestion. Alternatively, AURKA-GFP affinity-purification extracts were subjected to in-solution digestion. Peptide samples were separated by online reversed-phase (RP) nanoscale capillary liquid chromatography (nanoLC) and analyzed by electrospray mass spectrometry (ESI MS/MS). The experiments were performed with a Dionex UltiMate 3000 nanoRSLC chromatography system (Thermo Fisher Scientific/Dionex Softron GmbH) connected to a Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific) equipped with a nanoelectrospray ion source. Mass spectra data generated by the Orbitrap Fusion Tribrid instrument (\*.raw files) were analyzed with Byonic version 2.12.0 (Protein Metrics, San Carlos, USA) using the optimal search parameters (mass tolerances and post-translational modifications) generated by Preview version 2.12.0 (Protein Metrics, San Carlos, USA). Precursor mass tolerance was set to 2 ppm and the fragment mass tolerance was set to 0.2 Da. Both precursor and fragments m/z measurements were recalibrated based on Preview calculations. The following mass additions were used as variable modifications: oxidation of methionine, histidine and tryptophan \[+15.9949 Da\], dioxidation of methionine and tryptophan \[+31.9898 Da\], deamidation of asparagine and glutamine \[+0.9840 Da\], N-terminal protein acetylation \[+42.0105 Da\], phosphorylation of serine and threonine \[+79.9663 Da\], glutamine conversion to pyroglutamate \[−17.0265\] and glutamate conversion to pyruglutamate \[−18.0105 Da\]. Carbamidomethylation of cysteines \[+57.0214 Da\] was set as a fixed modification. A semi-specific trypsin digestion setting allowing for N- or C-ragged peptides was specified. Byonic was used to search the MS/MS data against the Uniprot human reference proteome (71 657 entries as of May 23, 2017) complemented with a list of common contaminants maintained by Protein Metrics and concatenated with the reversed version of all sequences (decoy mode). The Byonic automatic score cutoff option was specified to maintain the false discovery rate (FDR) for peptide spectrum matches (PSMs) in the range of 0--5%. The FDR for protein identifications was set to 1%. The cellular localizations and biological functions of identified proteins were further analyzed based on information available from the Gene Ontology (GO) classification tool available in DAVID Bioinformatics Resources (<https://david.ncifcrf.gov/>) ([@bib18]; [@bib19]). All peptide spectrum matches corresponding to AURKA peptides identified by Byonic were extracted from the peptide dataset for the identification of putative mitochondrial processing peptidases cleavage sites into AURKA. AURKA peptides containing N- and C-ragged termini were collected and classified relative to AURKA amino acid sequence. Only high quality peptides were considered by applying a stringent p value cutoff of 0.001 (i.e. a -log(p value) of 3.0). The number of occurrences of each non-tryptic cleavage sites was calculated and plotted relative to AURKA amino acid sequence. For the CRAPome filtering, protein datasets of affinity-purified AURKA-GFP-interacting proteins generated by LC-MS/MS analysis were grouped together to establish a repertoire of putative AURKA interactors (Supplementary Material). The protein list was filtered against CRAPome (<http://crapome.org/>), a contaminant repository database that scores high-confidence interaction data from AP-MS experiments. A group of 30 control AP-MS experiments based on the isolation of GFP-tagged proteins by anti-GFP antibodies coupled to magnetic Dynabeads was used as a reference database to score AURKA-GFP interactions. The CRAPome primary scores (FC-A) distribution was plotted to perform statistical analysis. The upper quartile, a value that cuts off 75% of protein identifications with the lowest FC-A scores was used as a cutoff criteria. Only the top-scoring 25% (641 out of 2601 protein IDs) proteins were accepted as putative AURKA-interacting proteins and used for Gene Ontology analysis.

Immunocytochemistry and widefield, confocal and FLIM microscopy {#s4-8}
---------------------------------------------------------------

Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich), stained using standard immunocytochemical procedures and mounted in ProLong Gold Antifade reagent (Thermo Fisher Scientific). The antibodies used were: primary monoclonal mouse anti-AURKA, 1:20 ([@bib12]); anti-GFP, 1:1000 (Sigma-Aldrich, 11814460001); polyclonal rabbit anti-PMPCB, 1:500 (Proteintech, 16064--1-AP); and secondary anti-mouse or anti-rabbit antibodies conjugated to Alexa 674 at a 1:500 dilution, Alexa 555 or 488 both at a 1:5000 dilution (Thermo Fisher Scientific). Cells displaying mitochondrial clusters were scored after viewing in a DMRXA2 microscope (Leica) equipped with a 63X oil-immersion objective (numerical aperture (NA) 1.32) and driven by MetaVue software (Molecular Devices). Multicolour images of cultured cells were acquired with a Leica SP8 inverted confocal microscope (Leica) and a 63X oil-immersion objective (NA 1.4) driven by LAS software or alternatively with a BX61WI FV-1000 confocal microscope (Olympus) driven by Olympus FV-1000 software and equipped with a 60X oil- immersion objective (NA 1.35). Multicolour images of *Drosophila* pupae were acquired with an SPE DM 5500 microscope (Leica) and a 63X oil-immersion objective (NA 1.4). The excitation and emission wavelengths for GFP/Alexa 488 were 488 and 525/50 nm, respectively; for mCherry/Alexa 555, they were 561 and 605/70 nm. GFP was used as a FRET donor in all experiments, and its decrease was measured by FLIM microscopy as in ([@bib6]). MitoDendra2 photoconversion was performed on a region of interest (ROI) with a 405 nm laser at 0.25% power for 5 msec on an inverted Leica SP8 confocal microscope. Images of the green (λ~ex~: 490 nm; λ~em~: 507 nm) and red (λ~ex~: 553 nm; λ~em~: 573 nm) species of mitoDendra2 were then acquired using a 63X oil-immersion objective (N.A. 1.4) and a hybrid detector, driven by the LAS software. The total number of red objects present 120 s after photoconversion was normalised to the number of red objects in the ROI in the first image obtained after the photoconversion procedure (5 s). Fluorescence co-localisation was calculated with the JaCoP plugin ([@bib8]) of the ImageJ software after applying an automatic threshold mask to the confocal images; AURKA-positive mitochondria in each cell cycle phase were calculated by normalising AURKA and PMPCB-co-localising objects to the total number of AURKA-positive objects. Mitochondrial aspect ratio and form factor were calculated from confocal images as in ([@bib24]). TMRM and mitoTimer fluorescence were acquired in a FluoSTAR OMEGA plate reader (BMG Labtech) equipped with 485/520 490 nm and 540/615 nm excitation/emission filters. When overexpressing AURKA or one of its variants for confocal microscopy, non-fluorescent 6xHis-tagged AURKA was used instead of GFP-AURKA where indicated.

Electron microscopy {#s4-9}
-------------------

For conventional electron microscopy, the cells were rinsed with 0.15 M sodium cacodylate and fixed by adding 2.5% glutaraldehyde for 1 hr. After fixation, the cells were rinsed several times with 0.15 M sodium cacodylate and post-fixed with 1.5% osmium tetroxide for 1 hr. After further rinsing, the samples were dehydrated in increasing concentrations of ethanol (50, 70, 90% and 100% v/v). The cells were gradually infiltrated with increasing concentrations of epoxy resin (30, 50, 70% v/v in ethanol) for a minimum of 3 hr per step. The samples were then incubated overnight in pure epoxy resin before continuing the infiltration procedure with a two-step incubation in 2,4,6-Tris(dimethylaminomethyl)phenol (DMP30, Sigma-Aldrich)-epoxy resin, first for 3 hr and then at 60°C for 24 hr to polymerise the samples *en bloc*. Ultra-thin sections of 80 nm were then cut from the blocks using a UCT ultramicrotome (Leica), placed on grids, and post-stained with uranyl acetate for 30 min and with lead citrate for 20 min. For immunoelectron microscopy, cells were centrifuged for 5 min at 800x*g*, recovered and rapidly fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M phosphate buffer (PB) for 4 hr as previously described ([@bib41]). The cells were rinsed in PB and suspended in gelatin (12% wt/vol) at 37°C for 10 min. After solidification on ice, the cell blocks were cut and immersed in 2.3 M sucrose at 4°C overnight. The blocks were then mounted on a pin holder and placed in a UC7 cryo-ultramicrotome (Leica). Rapid trimming was performed using a 90°C trim tool (DTB20, Diatome AG) at −80°C to determine a region of interest. Ultrathin cryosections (70--90 nm) were cut at −120°C using a dry diamond knife (DCIMM 3520, Diatome AG), picked up with a mixture (1:1 vol/vol) of 2.3 M sucrose and 2% wt/vol methylcellulose and transferred to formvar-coated copper or nickel grids. The grids were subjected to standard immunolabelling procedures ([@bib41]; [@bib15]; [@bib37]) before a final contrast on ice with a mix of 2% wt/vol methylcellulose and 4% wt/vol uranyl acetate in a ratio of 8:2. The combinations of primary and secondary antibodies used are listed in [Supplementary file 7](#supp7){ref-type="supplementary-material"}. The grids used for electron microscopy were examined at 120 kV with a JEOL 1400 (Peabody) transmission electron microscope equipped with an SC 1000 camera (Gatan Orius). Mitochondrial length, lysosomal abundance and number of gold beads were scored using the ImageJ software.

Flow cytometry {#s4-10}
--------------

Analyses of autophagy, apoptosis, mitochondrial membrane potential and proteasome peptidase activity were performed on a BD Accuri C6 flow cytometer (BD Biosciences). Annexin V-FITC/PI apoptosis detection kit was used as described by the manufacturer (Thermo Fisher Scientific). MAP1LC3A activation was measured using the FlowCellect Autophagy LC3 Antibody-based Assay Kit (Merck Millipore). Mitochondrial inner membrane potential was measured with the JC-1 probe (Thermo Fisher Scientific) as previously described ([@bib1]). The peptidase activity of proteasomes was monitored using the fluorogenic peptide succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin, LLVY-AMC (Sigma-Aldrich) ([@bib9]).

Statistical analyses {#s4-11}
--------------------

Two-way ANOVA tests were employed to compare two variables among multiple conditions, and one-way ANOVA when just one variables needed to be tested among multiple conditions. Student's t-test was employed to compare two conditions. Statistical tests were performed after testing data for normality. Two-way ANOVA and the Holm-Sidak method were used to compare the the effect of siRNAs and AURKA isoforms on the relative mitochondrial abundance of AURKA ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3E](#fig1s3){ref-type="fig"}), the effect of the pharmacological treatment and the mitochondrial respiratory parameter on mitochondrial respiration ([Figure 5L](#fig5){ref-type="fig"}) the effect of pharmacological treatment and the fluorescence protein on lifetime ([Figure 2D](#fig2){ref-type="fig"}), the effect of pharmacological treatment and transfection conditions on TMRM fluorescence ([Figure 5G](#fig5){ref-type="fig"}), the effect of time and transfection conditions or *Drosophila* genotypes on the number of mitoDendra2 red objects ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplements 4B--D](#fig3s1){ref-type="fig"} and [5](#fig3s2){ref-type="fig"}) and the effect of the pharmacological treatment and the cell line on mitochondrial aspect ratio and form factor ([Figure 4B](#fig4){ref-type="fig"}). One-way ANOVA and the Holm-Sidak method were used to compare the relative mitochondrial abundance of AURKA isoforms ([Figure 1B](#fig1){ref-type="fig"}), the number of AURKA-positive mitochondria ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), the effect of acceptors on FRET efficiencies for given donor-acceptor pairs ([Figures 3E](#fig3){ref-type="fig"} and [4F](#fig4){ref-type="fig"}, [Figure 1---figure supplements 2A](#fig1s2){ref-type="fig"}, [3C](#fig1s3){ref-type="fig"} and [6I](#fig3s3){ref-type="fig"}), Mander's co-localisation coefficients ([Figure 2B](#fig2){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), the relative total or mitochondrial abundance of AURKA with normal or kinase-dead AURKA ([Figure 2F](#fig2){ref-type="fig"}), the relative abundance of each oxidative phosphosphorylation complex ([Figure 5A](#fig5){ref-type="fig"}), the proportion of autophagic cells ([Figure 5C](#fig5){ref-type="fig"}), the percentage of cells showing mitochondrial aggregates ([Figure 3---figure supplement 6E](#fig3s3){ref-type="fig"}), the abundance of mitochondrial fusion and fission proteins ([Figure 3D](#fig3){ref-type="fig"}), proteasomal activity ([Figure 5D](#fig5){ref-type="fig"}), MitoTimer red/green ratio ([Figure 5E](#fig5){ref-type="fig"}), JC-1 red fluorescence ([Figure 5F](#fig5){ref-type="fig"}) and the percentage of live, dead or apoptotic cells ([Figure 5I](#fig5){ref-type="fig"}). One-way ANOVA on ranks and Dunn's method were used to compare mitochondrial length ([Figure 3A](#fig3){ref-type="fig"}). One-way ANOVA on ranks and the Kruskal-Wallis method were used to compare mitochondrial aspect ratio and form factor ([Figure 3---figure supplement 4A](#fig3s1){ref-type="fig"}) and the abundance of phosphorylated DNM1L forms and their ratios to total DNM1L ([Figure 3---figure supplement 6E](#fig3s3){ref-type="fig"}). Student's *t*-test was used to compare Mander's co-localisation coefficients ([Figure 1A](#fig1){ref-type="fig"}), the relative total or mitochondrial abundance of AURKA isoforms ([Figure 1B](#fig1){ref-type="fig"}, [Figure 3---figure supplement 3E](#fig3s3){ref-type="fig"}), the relative O~2~ flux ([Figure 5B and H](#fig5){ref-type="fig"}), *PMPCB* downregulation efficiency ([Figure 1C](#fig1){ref-type="fig"}), mitochondrial aspect ratio and form factor ([Figure 3---figure supplement 6C](#fig3s3){ref-type="fig"}), the abundance of mitochondrial fusion and fission proteins ([Figure 3C](#fig3){ref-type="fig"}), *AURKA* downregulation efficiency ([Figure 3C](#fig3){ref-type="fig"}) and the abundance of phosphorylated DNM1L forms and the ratios of these forms to total DNM1L ([Figure 3---figure supplement 6B](#fig3s3){ref-type="fig"}). Alpha for statistical tests used in this study was equal to 0.05.
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10.7554/eLife.38111.016

###### Identification of the semi-tryptic peptides of AURKA.

The cleavage sites identified by the analysis of AURKA N- and C-ragged semi-tryptic peptides of human AURKA are indicated. Cleavage sites shown in grey derive from peptides containing aromatic residues (Phe, Tyr, Trp) that spontaneously give rise to truncated semi-tryptic fragments during MS/MS analysis. The cleavage sites shown in red originate from semi-tryptic peptides, devoid of aromatic residues, which are potentially generated by the action of mitochondrial proteases.

10.7554/eLife.38111.017

###### Identification of the AURKA interactome at interphase.

We report on different pages: the protein UNIPROT IDs, the common biological contaminants obtained after the CRAPome analysis, the proteins with a known mitochondrial localization found among the AURKA interactome; the Gene Ontology (GO) cellular components and biological processes for the AURKA-interacting proteins and the known AURKA interactors found in this analysis.

10.7554/eLife.38111.018

###### Plasmid vectors used in this study.

This file includes the source of the plasmids, eventual cloning sites (when applicable) and primers used for site-directed mutagenesis.

10.7554/eLife.38111.019

###### *Drosophila* strains used in this study.

This file includes the name, the genotype and the source/identifier of the *Drosophila* strains used.

10.7554/eLife.38111.020

###### *Drosophila* crossings.

This file includes the genotype of the Drosophila crossings used in this study, together with the corresponding figure panels.

10.7554/eLife.38111.021

###### Primary antibodies used for western blotting.

This file includes the primary antibodies used in this study together with the brand name, the catalogue number and the dilution used.

10.7554/eLife.38111.022

###### Primary and secondary antibodies used for electron microscopy.

This file includes the primary and secondary antibodies used together with the brand name, the catalogue number and the dilution used.

10.7554/eLife.38111.023

Data availability {#s7}
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All data generated or analysed during this study are included in the manuscript and supporting files.
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Decision letter
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Jody

Reviewing Editor

University of Utah

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"Aurora kinase A localises to mitochondria and modifies mitophagy and energy production when over-expressed\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Jody Rosenblatt as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by a Senior Editor.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

As you will see, while the reviewers found the subject interesting, they found the study to be preliminary, making its interpretation confusing. The main problem we had was there was a lack of mechanistic insight about what substrate Aurora kinase A (AURKA) would phosphorylate to alter mitochondria function and turnover. Does it require RALA/DNM1L, NM1L, or an independent mechanism? Moreover, there was concern about the AurA localization at mitochondria, which changes in different pictures in the manuscript and is not supported in other studies cited below (and in a recent BioRxiv pre-print, which we do not use to compare but mention here for your interest), something that live imaging may better address. Without a clear understanding of where AurA dynamically localizes and what it signals to in mitochondria, it is hard to clearly determine whether it has a primary role in mitochondria fission or secondary function from its role in mitosis. Unfortunately, at present, the model proposed is speculative and not sufficiently supported by the data.

Reviewer \#1:

The manuscript by Bertolin et al. demonstrates a new role for AURKA in controlling mitochondrial activity and mitophagy during interphase. While previous roles for AURKA have focused predominantly on its role in mitosis regulation, this paper represents an important departure indicating its role in controlling mitochondrial form and function. They show that AURKA gets imported and cleaved at mitochondria and its loss through knockdown disrupted mitochondrial turnover and function, leading to longer mitochondria. Because increased AURKA and an activating mutation are frequent in cancer, they next examined how overexpression or expression of the mutant affects mitochondria and found that it promotes increased respiration, and fusion, while reducing the overall total mass of cellular mitochondria. This study is very interesting suggesting a new role for AURKA on mitochondrial function and turnover, which may have important implications for its overactivation in cancer cells.

1\) The study is overall compelling and well written, with helpful diagrams. One point that is confusing is the mechanism by which AURKA may function. This may go beyond the depth of this study, however, it makes the findings that both overexpression and loss of AURKA lead to longer mitochondria somewhat confusing. It would be useful (at least in the Discussion) to address how both loss and gain of function could lead to similar phenotypes. Does this mean that normally, AURKA is controlling mitochondrial quality by degrading non-functional mitochondria but when overexpressed it increases fusion of functional mitochondria. This point is interesting but confusing.

a\) With respect to this point, what does this sentence mean? \"These results suggests that AURKA maintains mitochondrial fission when expressed at physiological levels, and in its absence a compensatory fusion could be established as a consequence of lack of fission.\"

2\) Since there is much discussion about the role of increased AURKA function in cancer, they should provide more data regarding the prevalence of AURKA overexpression or mutations in different cancers. How common is it? Is it an indicator of poor prognosis or restricted to certain types of cancers? Do you see similar mitochondrial hallmarks in these cancers or do other mutations alter the phenotypes?

*Reviewer \#2:*

This paper reports the association of AURKA, which is often amplified in particular types of cancer, with mitochondrial. The authors report that AURKA is imported into the mitochondrial matrix via the TOMM complex and is cleaved by processing proteases in the mitochondria. The authors claim that AURKA is active in the mitochondrial matrix and alters a host of mitochondrial parameters with either depleted or overexpressed. The author\'s data is interpreted to indicate \"functional\", physical and direct interactions with a variety of diverse proteins involved in mitochondrial dynamics and electron transport chain function. AURKA within the mitochondria is also associated with alterations in rates of mitophagy.

In my opinion, the data described here is not really believable nor is its physiological significance clearly demonstrated. The entire story rests on there being a pool of AURKA that is imported into mitochondria. Even this conclusion seems dubious. AURKA isn\'t found in either Mitocarta or Mitominer, suggesting that dozens of experiments integrated to make these databases have failed to identify AURKA in this compartment. Although there could of course be proteins that are mitochondrial that have been missed as being mitochondrial, the absence of AURKA in combination with the absence of a clear mitochondrial targeting sequence in its N-terminus raises questions.

One must then wonder how the authors either see signals for AURKA overlapping with mitochondria or the presence of processed AURKA in extracts, with the processed form diminished upon depletion of the supposed mitochondrial protease PMPCB. One possibility for the processing seen in extracts is that cell lysis results in release of the protease from the mitochondria that has the ability to cleave AURKA, a possibility that wasn\'t tested. The import model is seemingly made even more unlikely in that they claim that a GFP-AURKA-Cherry fusion is also recognized and imported into mitochondria. It is hard to see, given how the translocon and mitochondrial target sequences work, that this construct would be successfully imported into mitochondria and cleaved by PMPCB.

The authors perform essentially every mitochondrial assay available to them to provide evidence of effects on mitochondrial function, either by depletion of AURKA or overexpression (at leaves that appear to be \~100-fold or more higher than endogenous). Many of these assays end up being descriptive, and they paint a bewilderingly complex interplay between AURKA and mitochondria, which makes it hard to put any specific finding into a logical biological process. As an example, the authors employ immunoprecipitation of overexpressed AURKA-GFP followed by mass spectrometry and identify 2600 proteins (approximately 25% of the expressed proteome in these cells), including 449 mitochondrial proteins. They apparently have no negative controls and try to make the conclusion that because certain mitochondrial proteins are detected, that they are likely real and direct. It is well known that the vast majority of proteins present on anti-GFP resin are non-specific binders, but they haven\'t tried to control for this. So ultimately, they do not rigorously demonstrate that the proposed interactions with proteins that are both in the inner membrane and function at the outer membrane during fission are specific or not. Thus, it becomes very cloudy in terms of how AURKA is working. Is its main function(s) within the matrix or in the cytoplasm in the context of fission with DNM1L/MFF?

For the vast majority of experiments, the authors use either a single siRNA or a single shRNA. Thus, there are no experiments to demonstrate the absence of off target effects for any individual RNAi reagent. Given that many of the effects are small, it is conceivable that some of the conclusions drawn are based on off-target effects.

Additionally, in Figure 3 the authors conclude that high levels of AURKA lead to increases in Complex IV, but no substantial changes in other electron transport chain complexes. The weird thing here is that siRNA against AURKA also lead to slight increases in Complex IV levels, which doesn\'t make sense. One would think there would be opposite activities. The physiological significance of most of the measurements in this figure isn\'t clear.

Many of the conclusions just don\'t make sense and could result from overexpression effects. For example, they state \"Last, no LAMP1 staining was observed in cells over-expressing AURKA ΔNter (Figure 6C), strongly suggesting that the mitochondrial pool of AURKA is responsible for mitophagy activation.\" It makes no sense that overexpression would completely remove LAMP1 staining in cells. Does this suggest that there are no lysosomes, for example? The authors do not look any further than this but make the conclusion that AURKA regulates autophagy -- a complete non-sequiter.

Finally, the authors try to link AURKA to mitophagy. They claim they use accepted assays but this really isn\'t the case. The TEM assay is very difficult to quantify, and overall they are looking at very small numbers of cells and trying to make conclusions. It isn\'t clear why they didn\'t use either the accepted mito_keima flux assay or alternatively use anti-DNA immunofluorescence, which allows quantification of the amount of mitochondria based on the mitochondrial DNA abundance. Both of these assays are highly used in the field.

Based on these and many other issues with the paper, I cannot support publication in *eLife*. I think a much more rigorous analysis would need to be done. Moreover, if AURKA is functioning as a kinase in the mitochondria, what are its substrates and how does phosphorylation by AURKA alter their functions.

Reviewer \#3:

In this manuscript, Aurora A is proposed to play a critical role in regulating mitochondrial fusion, mitophagy and metabolic reprogramming in cancer cells. Aurora A localizes to the mitochondria during interphase, it is active as a kinase in this organelle, and its depletion results in significant changes in mitochondria morphology. These effects seem to be mediated by changes in DNML1 activity. The Phe31Ile variant of AURKA, a mutant found in cancer patients and previously described as a tumour-susceptibility factor, displays increased mitochondrial import and ATP production, and results in and accelerated mitophagy. Altogether, these results suggest that AURKA over-expression can promote metabolic reprogramming by inducing specific changes in the mitochondrial network.

In general, the data showing mitochondrial localization of Aurora A are solid and highly interesting and it is also clear that AurkA overexpression induces significant morphological and functional changes in mitochondria. Major remaining question is whether these changes are a consequence of the a) AurkA-NML1 interaction, b) the established RALA-DNML1-dependent pathway that controls mitochondrial fission/fusion or c) a fusion/fission-independent pathway as suggested by the Phe31Ile mutant. Some of these questions are acknowledged in the Discussion but it seems that the information in the manuscript remains a bit preliminary until some of these questions are addressed more in detail.

1\) The localization of AurA seems to be variable in the different images shown. For instance is only cytoplasmic in Figure 1 (or Figure 2D) with certain spotted (mitochondria) pattern, but is both cytoplasmic and nuclear in Figure 2B, C with no evidences of spotted (mitochondrial pattern). One possibility is that cell in Figure 1 is G1 whereas it might be S/G2 in Figure 2. The authors should clarify the pattern of Aurora A localization (and co-localization with mitochondria) in the different cell cycle stages.

2\) It is somehow surprising that OCR does not change after Aurora A knockdown. I wonder whether the knockdown levels are not sufficient. The authors should also use AurkA inhibitors to test mitochondrial activity (Seahorse).

3\) On a related issue, how did the authors manage to prevent secondary consequences of cell cycle arrest/defects in these assays? Does changes in mitochondria induced by AurkA occur in parallel to changes in cell cycle phases (entry into G2 etc.)?

4\) It is not clear whether the authors are proposing a direct activity of Aurora A on DNML1-Ser637? Or changes in Ser 637 are RALA-dependent following the already established pathway? A direct interaction between AurkA and DNML1 is suggested by the proteomics data but the authors do not evaluate this functionally. One would assume that is a RALA-dependent process but his has not been tested and RALA apparently was not present in these complexes. This mechanism should be analyzed in detail and properly clarified. Perhaps rescue assays with RalA, DNML1 would help.

5\) Data with the Phe31Ile mutant are quite interesting and this mutant has a significant effect in mitophagy and mitochondrial activity. However, given the lack of specific mechanism as discussed in the previous point, it is not completely clear why this mutant induces these effects. The authors indicate that the mutations favors entry into the mitochondria; however, no changes in interconnectivity are shown. As mitophagy was previously proposed to be triggered or favored by these changes in connectivity, the actual reason for the phenotype induced by the AurkA mutant is not really clear. In addition, these data actually argue against the DNML1-fusion mechanism proposed in the earlier figures in the manuscript.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"Aurora kinase A dynamically localises to mitochondria to control mitophagy and energy production\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Andrea Musacchio (Senior Editor), a Reviewing Editor, and three reviewers.

On the whole, there was consensus that the paper was much improved. However, some remaining issues were identified that need to be addressed before acceptance, as outlined below:

All three reviewers found the data on mitophagy not particularly convincing. There was also concern that the cancer data was not as well-developed as it might be with respect to rescuing the mutation and imaging. Therefore, we suggest that you also omit this part of the story unless you feel that it can be better supported. These are our only requests required for acceptance. I include the comments of the reviewers below only for your own reference and feedback.

We look forward to receiving a revised version of the manuscript that addresses these final issues.

*Reviewer \#1:*

In the revised version of the manuscript Bertoli et al. have added a bunch of interesting results that help to delineate the possible role of Aurora A at mitochondria. In particular, the finding that Aurora A needs to be at the mitochondria and this localization is RALA independent makes an important observation after the Kashatus 2011 manuscript. Some other controls and complementary techniques (cell cycle analysis, mitotracker, etc.) added also help to reach more solid conclusions.

The only comment I have is that the characterization of the Ph31Ile mutant is a bit preliminary to make so strong conclusions. Yet, this is a very important point in the manuscript (demonstrating that a cancer-associated mutation in Aurora A functions by modulating mitochondria rather than cell cycle functions). I would suggest to testing whether the effect of the Phe31Ile mutant can be rescued by a second mutation that prevents the localization at the mitochondria.

Reviewer \#2:

I was asked by *eLife* to comment on the manuscript by Bertolin et al. after the first round of reviewing. So I had a chance to evaluate both the paper and the answers to reviewers remarks. This manuscript reports on the essential findings, which was quite surprisingly overlooked before by many researches working on this kinase, that AURKA is localizes to mitochondria and is important for mitochondria functioning and quality control. To demonstrate this new role of AURKA, authors apply various approaches, including extensive microscopy analysis and proteomics, to study the consequences of AURKA depletion or overexpression on mitochondria fate, both in \"normal\" and cancer cells. I think that authors provided convincing answers to the concerns raised by reviewers and provided a new sets of experiments, which improve their initial observation. Nevertheless, I have a couple of remarks, that would be useful to address.

1\) I am not quite convinced by the experiments that describe AURKA localization at different phases of the cell cycle (Figure 1A and Figure 1---figure supplement 1A). It does not look like the cells were synchronized at different phases. There is no description of any time-lapse experiments either. So either the AURKA localization through the cell cycle has to be studied more thoroughly or authors delete their statement (and corresponding figures) from the current version of the manuscript.

2\) Although many concerns of the reviewer \#2 were properly addressed, one of them, concerning mitophagy, still looks not fully proved. The point is that the majority of the experiments are set-up to follow general autophagy, but not mitophagy. I am confused by the new experiment added (Supplementary Figure 7B), which reports the fluorescence of Lysosomal marker, LysoTracker Red. What it is supposed to demonstrate? Using experiment with *Drosophila* cells is also confusing. Why *Drosophila* suddenly? What it is about *Drosophila* that cannot be done in HEK 293? (see subsection "Over-expressed AURKA triggers mitophagy of fragmented mitochondria", first paragraph, Figure 6E). TEM assay was a concern of reviewer \#2 and was not addressed in the response to reviewers. Figure 6C looks very strange (huge, probably lysed, areas around \"potential\" autophagosomes). I would honestly remove TEM experiments and replace them either with Western blots showing degradation of mitochondrial markers (HSP60, Tim50) or indeed use use mito-keima flux assay, as suggested by reviewer \#2 (with tools already commercially available). That said I could also suggest to authors that for this paper they might omit description of results concerning mitophagy and address them in another project, in a future paper. This can be an opportunity to study the role in AURKA in mitophagy regulation in more details, more properly. This manuscript can stand on its own even without mitophagy.

Reviewer \#3:

In the manuscript by Bertolin et al. the authors provide some evidence supporting a role for Aurora A (AURKA) kinase in control of mitochondrial function, including ATP production, membrane dynamics and mitophagy. Thus, this work could establish a novel role for AURKA in interphase cells, as opposed to well established mitotic function of this protein. Some data (e.g. mitochondrial localization of AURKA) are convincing, with appropriate controls, and well discussed. However, the majority of this work relies on correlative evidence, and mechanistic insights into how AURKA control mitochondria are missing. There are some inconsistences in data interpretation, and many conclusions (especially regarding mitophagy) are not supported by high quality data. Furthermore, some techniques used in this work should be supported by a more appropriate quantitative methods (especially mitophagy analyses).

1\) While convincing, the FRET/FLIM data (Figure 2) should be supported by additional controls. Can the authors provide the evidence that other abundant OMM proteins do not show fluorescence lifetime alterations when co-overexpressed with AURKA?

2\) The fact that overexpressed AURKA shows abundant cytosolic localization does not support the notion that AURKA is reexported from the mitochondria to the cytosol, as proposed (subsection "AURKA localises in the mitochondrial matrix via an N-terminal MTS and it undergoes a double proteolytic cleavage", fifth paragraph). Many mitochondrial proteins when overexpressed localize to the cytosol, but rather through defects in protein import, than their export to the cytosol. The issue of AURKA export from the mitochondria, while potentially interesting, should be supported by stronger data. For example, can the authors use photactivable -GFP tagged AURKA, or some photobleaching assay to test this issue more directly?

3\) It is surprising that some data on mitochondrial function in AURKA knockdown and overexpression were generated HEK293 or MCF7 cells, but mitochondrial fusion assays shown in Figure 4 were done using *Drosophila* cells. Can the authors justify why they do not move mammalian cell data (currently Figure 3---figure supplement 4) into the main figure?

4\) The authors claim a direct role for AURKA in mitochondrial dynamics. However, these conclusions are based on mostly correlative data, and the possibility that other events affected in AURKA RNAi and AURKA-overexpressing cells contribute to this process, and the observed effect is not direct. Ideally, more data on directness of this mechanism would make this work much stronger. However, if this is not possible, then at least the authors should tone down their conclusions.

5\) Generally, the mechanism by which low and high levels of AURKA show distinct effects on mitochondrial fusion and fission should be considered with more depth and supported by some additional evidence. Data provided in a current version of this work make it difficult to evaluate the underlying mechanisms.

6\) The imaging data on mitochondrial morphology in four breast cancer cell lines is less convincing. For example, in case of MDA-MB-2311 cells one panel (DMSO-treated cells) show small cells with perinuclear mitochondria, the other one (MLN8237-treated cells) shows multinuclear large cell. Furthermore, inserts showing magnified mitochondria in each cell type would make data analysis/evaluation much easier. The authors should also show some additional data testing the possibility that the underlying mechanism is indeed conserved (perhaps Drp1 phosphorylation levels).

7\) The mitophagy data is not very convincing. In addition to measuring mitochondrial mass/area, more direct mitophagy assays (e.g. mito-Keima) should be performed to verify the effects of AURKA expression on this process. Furthermore, the authors claimed that overexpression of AURKA directly regulates mitochondrial fusion (e.g. Figure 4). They also stated that there are changes in expression of some fusion proteins (relatively minor). However, Figure 6 shows \~50% decrease in mitochondrial mass. Why such dramatic differences in fusion protein are not observed in Figure 4. Is Opa1 somehow spared from degradation? This is very confusing and should be addressed. For example, total cell lysates should be analyzed for expression levels of many distinct mitochondrial proteins (and non-mitochondrial controls) and their changes in AURKA-depleted, AURKA-overexpressing and control cells quantified. Furthermore, why the authors do not analyze LCIII localization in mammalian cells, but instead use *Drosophila*?

8\) LCIII is not cleaved upon activation of mitophagy (as stated here), changes in LCIII mobility are due to conjugation to the head group of the phosphatidylethanolamine. This should be corrected.

10.7554/eLife.38111.028

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

As you will see in our point-by-point response, we have carefully addressed each of their concerns with new figures throughout the manuscript, detailed explanations or with a more appropriate discussion of our data. These new elements are now highlighted in the manuscript. We are confident that you and the reviewers will find in our revised manuscript convincing answers in response to the key points raised.

> Reviewer \#1:
>
> \[...\] 1) The study is overall compelling and well written, with helpful diagrams. One point that is confusing is the mechanism by which AURKA may function. This may go beyond the depth of this study, however, it makes the findings that both overexpression and loss of AURKA lead to longer mitochondria somewhat confusing. It would be useful (at least in the Discussion) to address how both loss and gain of function could lead to similar phenotypes. Does this mean that normally, AURKA is controlling mitochondrial quality by degrading non-functional mitochondria but when overexpressed it increases fusion of functional mitochondria. This point is interesting but confusing.

First, we would like to thank Dr. Rosenblatt for her positive and helpful comments on the content and on the style of our manuscript.

To answer the first comment:

The similarities

In the case of a loss of function of AURKA there is a lack of fission, and as a consequence the mitochondria network looks highly interconnected. In the case of a gain of function/overexpression there is an increase in fusion and in mitophagy that eliminates small damaged mitochondria. Again, the mitochondria network look highly interconnected.

The differences

In the case of AURKA loss of function, the mitochondrial mass and the ATP production remain unchanged compared to controls. In the case of gain of function, there is a loss of mitochondria mass (around 40%) due to mitophagy and an increase in ATP production.

To shade light on this apparent discrepancy concerning the morphology of the mitochondrial network, we provide additional results and we discuss them more in depth in the corresponding Discussion section. In agreement with a similar request from reviewer \#3 (c.f. point 2 of the response to reviewer \#3), we provide new evidence that cells where AURKA is inhibited with MLN8237 show no differences in mitochondrial respiration compared to controls (new Figure 3L, subsection 2 Over-expressed AURKA increases the abundance of mitochondrial complex IV and up-regulates ATP production", second paragraph). This is in agreement with the similar effect of *AURKA* gene silencing on mitochondrial respiration (Figure 3H). However, MLN8237 induces mitochondrial elongation in four carcinoma cell lines routinely used for cancer cell biology (new Figure 5B, subsection "AURKA regulates mitochondrial fusion when over-expressed", third paragraph), as treatment with an AURKA-specific siRNA does. Although it is true that the morphology of mitochondria in cells treated with MLN8237 is comparable to the one of cells overexpressing AURKA, in the case of overexpressed AURKA a positive selection of mitochondria (through mitophagy and fusion) enhances mitochondrial ATP production.Instead, at physiological levels, AURKA promotes mitochondrial fragmentation and this is revealed by an increased mitochondrial interconnectivity when AURKA is silenced or inhibited. Under these conditions, there is no positive mitochondrial selection and thus no increase in ATP production. This is in agreement with data from Kashatus et al. (2011), where a dominant-negative version of AURKA also promotes mitochondrial fusion. We hope that these new results will help clarifying the action of AURKA on mitochondrial morphology according to its abundance.

> a\) With respect to this point, what does this sentence mean? \"These results suggests that AURKA maintains mitochondrial fission when expressed at physiological levels, and in its absence a compensatory fusion could be established as a consequence of lack of fission.\"

We thank the reviewer for this comment. We modified the sentence as follows: "These results indicate that AURKA maintains mitochondrial fission when expressed at physiological levels and that mitochondrial interconnectivity in the absence of AURKA is a consequence of a lack of fission. This results in the mere accumulation of elongated mitochondria without any increase in the energetic capabilities of the mitochondrial network". We hope that this new statement improves the clarity of the conclusion.

> 2\) Since there is much discussion about the role of increased AURKA function in cancer, they should provide more data regarding the prevalence of AURKA overexpression or mutations in different cancers. How common is it? Is it an indicator of poor prognosis or restricted to certain types of cancers? Do you see similar mitochondrial hallmarks in these cancers or do other mutations alter the phenotypes?

At present, increased copy number of the AURKA gene region is generally associated with an aggressive disease and poor patient survival. The AURKA gene region is located on chromosome 20, and its amplification includes the enhanced expression of additional genes (e.g. genes regulating cell cycle progression, and the most well-described AURKA interactor TPX2) (Belt et al., 2012; Sillars-Hardebol et al., 2011). In addition, the overexpression of AURKA has been linked with chromosomal instability (Baba et al., 2009). These events are common in different cancer types as in ovarian, pancreatic, lung and colon cancers and lead to bad prognosis. For instance, the increased copy number of AURKA is associated with the evolution of colorectal polyp into carcinoma (Carvahlo et al., Gut 2009). In breast cancer, the overexpression of AURKA is also linked to poor survival and it is associated with the overexpression of the human growth factor receptor 2 (HER2) and progesterone receptor (Nadler et al., 2008). Although epithelial cancers are non-glycolytic tumours and use the OXPHOS chain to produce ATP (Whitaker-Menezes et al., 2011), none of the above-mentioned studies took into account mitochondrial dysfunctions caused by or appearing in the presence overexpressed AURKA. Our study is thus pioneer in correlating for the first time this multifaceted kinase and mitochondrial physiology. This paragraph has been inserted in the Discussion, first paragraph.

We also provided additional data concerning four different breast cancer cell lines (other than MCF7), where AURKA is differentially abundant (New Figure 5, subsection "AURKA regulates mitochondrial fusion when over-expressed", third paragraph). All these carcinoma cell lines show the recruitment of AURKA at mitochondria and the interconnectivity of the mitochondrial network is positively correlated with the abundance of AURKA.

We hope that these explanations together with the additional data provided will now be judged sufficient.

> Reviewer \#2:
>
> \[...\] In my opinion, the data described here is not really believable nor is its physiological significance clearly demonstrated. The entire story rests on there being a pool of AURKA that is imported into mitochondria. Even this conclusion seems dubious. AURKA isn\'t found in either Mitocarta or Mitominer, suggesting that dozens of experiments integrated to make these databases have failed to identify AURKA in this compartment. Although there could of course be proteins that are mitochondrial that have been missed as being mitochondrial, the absence of AURKA in combination with the absence of a clear mitochondrial targeting sequence in its N-terminus raises questions.

We agree with the reviewer that the MTS of AURKA is rather unconventional. There is no aminoacidic consensus or similarity when we compared it to the most extensively described MTS in the literature. It is also true that the software predicting the existence of a putative MTS in public databases (e.g. MitoCarta, Mitominer) mostly fail in recognising AURKA as a mitochondrial protein. Despite this, it is known that there is no "standard" MTS sequence or consensus (even fully characterised MTS show a quite high degree of plasticity), that MTS differ according to the final intramitochondrial localisation (Reviewed in Chacinska et al., 2009), and that the majority of this prediction software is set to recognise proteins targeted to the matrix with a higher affinity than the other classes of sub-mitochondrial proteins. For all these elements, AURKA might have failed being classified as a mitochondrial protein. However, we believe that we provide sufficient elements in our manuscript to support the conclusion that AURKA is indeed mitochondrial.

Remarkably, it has recently been published that a pool of the kinase localises at the kinetochore, although public databases failed in detecting AURKA as a kinetochore-bound protein (Courthéoux et al., J Cell Sci 2018). Therefore, it is also conceivable that a pool of AURKA is mitochondrial, without it being recorded so far.

We indeed acknowledged that the MTS of AURKA is not conventional. We were indeed very surprised by the fact that unlikely the majority of "conventional" MTS, this one allows the mitochondrial import of the protein even with a fluorophore at its N-terminus (Figure 2D and E, subsection "AURKA is enzymatically active at the mitochondria", first paragraph). This strongly suggests that the conventional MTS located at the N-terminus are not the rule and that the amino acid sequence might not be the sole criterion for importing a protein into mitochondria. Other criteria such as the structure of the protein or its post-translational modifications could be involved. In this light, our molecular modelling approach provides evidence that changes in the three-dimensional conformation of the MTS (e.g. when comparing normal AURKA or the cancer-related variant F31I, Figure 8A and B, subsection "The cancer-related AURKA Phe31Ile is more imported into mitochondria and it accelerates mitophagy and ATP production", first paragraph) impact the import of the kinase.

The fact that AURKA is imported into mitochondria and that it bears a "cryptic" and unconventional MTS has also been reported by a competitor team in a recent BioRXiv preprint (Grant et al.), while our manuscript was under review.

> One must then wonder how the authors either see signals for AURKA overlapping with mitochondria or the presence of processed AURKA in extracts, with the processed form diminished upon depletion of the supposed mitochondrial protease PMPCB. One possibility for the processing seen in extracts is that cell lysis results in release of the protease from the mitochondria that has the ability to cleave AURKA, a possibility that wasn\'t tested. The import model is seemingly made even more unlikely in that they claim that a GFP-AURKA-Cherry fusion is also recognized and imported into mitochondria. It is hard to see, given how the translocon and mitochondrial target sequences work, that this construct would be successfully imported into mitochondria and cleaved by PMPCB.

We understand the reviewer's concern. The reviewer is concerned by the fact that AURKA might be cleaved during the process of protein extraction that put together the kinase and mitochondria PMPCB protease. The import signature, intended as two bands on immunoblots which reflect a double cleavage inside mitochondria, could thus reflect a non-physiological protease activity of PMPCB, acting only in the extract. To convince the reviewer, (1) we are using standard procedures to extract mitochondria, thoroughly employed in the literature (2) we performed additional total protein lysis using Laemmli sample buffer. As the reviewer knows, the advantage of using Laemmli as a lysis buffer is that it induces a complete inhibition of all enzymatic activities while lysing the cells. Under these conditions, the AURKA~38~ band is still present in cells transfected with a control siRNA. This indicates that AURKA~38~ band is not due to the mitochondrial fractionation procedure (see [Author response image 1](#respfig1){ref-type="fig"}, red arrowhead), but it is present in the cell.

![Total lysates from HEK293 cells obtained by immediate lysis in Laemmli sample buffer.\
Cells were blotted for endogenous AURKA, TUBA1A and PMPCB. AURKA~46~ and AURKA~38~ are indicated with a blue and red arrowhead, respectively.](elife-38111-resp-fig1){#respfig1}

> The authors perform essentially every mitochondrial assay available to them to provide evidence of effects on mitochondrial function, either by depletion of AURKA or overexpression (at leaves that appear to be \~100-fold or more higher than endogenous). Many of these assays end up being descriptive, and they paint a bewilderingly complex interplay between AURKA and mitochondria, which makes it hard to put any specific finding into a logical biological process.

The reviewer also complains about the number of assays done to investigate the role of AURKA at mitochondria, which is too elevated in his opinion. We were very surprised by this comment and we believe that this is not the case, as only by screening multiple and diverse parameters of mitochondrial functionality we could see the action of physiological AURKA in maintenance of mitochondrial morphology, and the one of overexpressed AURKA in ATP production and autophagy. Given that reviewer \#3 asks for more data in support of the role of overexpressed AURKA in ATP production (c.f. point 2 of the response to reviewer \#3), it is clear that the number of assays claimed to be excessive were actually not sufficient.

> As an example, the authors employ immunoprecipitation of overexpressed AURKA-GFP followed by mass spectrometry and identify 2600 proteins (approximately 25% of the expressed proteome in these cells), including 449 mitochondrial proteins. They apparently have no negative controls and try to make the conclusion that because certain mitochondrial proteins are detected, that they are likely real and direct. It is well known that the vast majority of proteins present on anti-GFP resin are non-specific binders, but they haven\'t tried to control for this. So ultimately, they do not rigorously demonstrate that the proposed interactions with proteins that are both in the inner membrane and function at the outer membrane during fission are specific or not. Thus, it becomes very cloudy in terms of how AURKA is working.

We thank the reviewer for this comment. The mitochondrial proteome of AURKA obtained by MS/MS data that we presented in the first version of the paper corresponded to the raw data without any cut-off procedure. We now inserted stringent filter to present our data. First, we eliminated all the proteins corresponding to only one or two peptides in the MS/MS data. Then, we filtered our data by excluding common contaminants non-specifically binding to anti-GFP beads and present in the CRAPome database. All the experimental details were updated in the new version of the manuscript, in the Mass spectrometry section of the Materials and methods. We now have a list of 641 putative AURKA-interacting proteins in all cellular compartments, as reported in the new Supplementary file 2. Again, we noticed that mitochondrial proteins are overrepresented (new Supplementary file 2 and Figure 5---figure supplement 7; Discussion, third paragraph).

> Is its main function(s) within the matrix or in the cytoplasm in the context of fission with DNM1L/MFF?

Given the multiple functions of overexpressed AURKA in the mitochondrion, and asks which one is the predominant. A wave of reports in the last two decades revealed that changes in mitochondrial dynamics and mitophagy are tightly intertwined. Changes in mitophagy cannot occur in the absence of dramatic alterations in the morphology of the mitochondrial network and in its energetic capabilities. Given that AURKA can act on three levels -- mitochondrial dynamics, mitophagy and ATP production -, it is hard to discriminate which change comes first. Most likely, there is a continuum of undetectable micro-changes happening simultaneously; with the tools available nowadays, these changes become visible only when they are already broadly activated. In this light, the development of new tools to detect more subtle modifications in mitochondrial physiology will represent a significant breakthrough in the field in the next years. In addition, the functional characterization of the AURKA interactome is certainly a goal in understanding the role of mitochondrial AURKA more precisely. However, we feel this is beyond the scope of the present paper.

> For the vast majority of experiments, the authors use either a single siRNA or a single shRNA. Thus, there are no experiments to demonstrate the absence of off target effects for any individual RNAi reagent. Given that many of the effects are small, it is conceivable that some of the conclusions drawn are based on off-target effects.

The reviewer is also concerned by the validity of our siRNA/shRNA approach. We agree that we did not perform any rescue of these siRNA/shRNA experiments. We would like to underline that our results are supported by the data obtained in the *Drosophila* model (Figure 4 and Figure 3---figure supplement 4;subsection "AURKA regulates mitochondrial morphology", last paragraph). In this organism we employ mutants inducing a full knock-out of the protein to analyse the mitochondrial network connectivity and mitophagy. We believe that this parallel approach is much more relevant than siRNA/rescue. In addition, we also employ the pharmacological inhibitor of AURKA MLN8237 to support our conclusions on the role of AURKA in mitochondrial morphology (new Figure 5B, subsection "AURKA regulates mitochondrial fusion when over-expressed", third paragraph).

> Additionally, in Figure 3 the authors conclude that high levels of AURKA lead to increases in Complex IV, but no substantial changes in other electron transport chain complexes. The weird thing here is that siRNA against AURKA also lead to slight increases in Complex IV levels, which doesn\'t make sense. One would think there would be opposite activities. The physiological significance of most of the measurements in this figure isn\'t clear.

The reviewer asks why only Complex IV of the mitochondrial respiratory chain is increased in conditions of AURKA-overexpression. This scenario is actually quite common in the field of mitochondrial disorders, where slight deficiencies in single complexes (often due to mtDNA mutations) can act alone in decreasing the functionality of the entire mitochondrial respiratory chain. This gives rise to complex, early-onset myopathies and neurological disorders (reviewed in Schapira, Lancet 2012). Although AURKA does not appear to be an integral protein of the mitochondrial respiratory chain, we believe that its interaction with several subunits of this chain could participate in producing excessive quantities of ATP.Of note, the siRNA against AURKA does not increase Complex IV levels as shown in Figure 3A and in the corresponding quantification (subsection "Over-expressed AURKA increases the abundance of mitochondrial complex IV and up-regulates ATP production", first paragraph).

> Many of the conclusions just don\'t make sense and could result from overexpression effects. For example, they state \"Last, no LAMP1 staining was observed in cells over-expressing AURKA ΔNter (Figure 6C), strongly suggesting that the mitochondrial pool of AURKA is responsible for mitophagy activation.\" It makes no sense that overexpression would completely remove LAMP1 staining in cells. Does this suggest that there are no lysosomes, for example? The authors do not look any further than this but make the conclusion that AURKA regulates autophagy -- a complete non-sequiter.

The reviewer is concerned by the assays we used to determine the impact of AURKA in the elimination of dysfunctional organelles by mitophagy. The first question raised is on the lack of LAMP1-labeled lysosomes in AURKA ΔNter-transfected cells and on whether this means that there are no lysosomes in these cells. To answer this concern, we analysed the fluorescence intensity of LysoTracker Red by flow cytometry in cells transfected with an empty vector or with AURKA ΔNter (newFigure 5---figure supplement 1B; subsection "fluorescence measured by flow cytometry. n=3 independent experiments with at least 30,000 cells per", second paragraph). No difference was detected in the two conditions, showing that lysosomes are equally present and unaffected in their abundance. The absence of LAMP1 in cells transfected with AURKA ΔNter might be the readout of an impaired or slowed targeting of lysosomes to mitochondria, or being linked to defective lysosomal composition. In both cases, this could result in defective mitochondrial degradation by mitophagy. The lysosomal composition and the correct targeting of lysosomes have already been described to play an important role in paradigms of cytotoxicity mediated by Natural Killer cells (Kzrewski et al., Blood 2013). These two aspects and their dependency on AURKA have not been evaluated in our study. Although very interesting, we believe this falls out of the scopes of our paper.

Further evidence that AURKA does not only impact LAMP1 abundance but global mitochondrial mass is also presented in the paper, underlining that LAMP1 is not a preferential/unique target of AURKA. It should rather be considered as an event falling in a pathway which perturbs mitochondrial functionality.

> Finally, the authors try to link AURKA to mitophagy. They claim they use accepted assays but this really isn\'t the case. The TEM assay is very difficult to quantify, and overall they are looking at very small numbers of cells and trying to make conclusions. It isn\'t clear why they didn\'t use either the accepted mito_keima flux assay or alternatively use anti-DNA immunofluorescence, which allows quantification of the amount of mitochondria based on the mitochondrial DNA abundance. Both of these assays are highly used in the field.

We thought our assays are standard in the field, as reviewed in Klionsky et al., 2016 (electron microscopy, LC3 cleavage assessed by biochemical approaches, fluorescence microscopy to localise LC3 and LAMP1 to mitochondria, to calculate the fluorescence intensity of an LC3-timer construct, and to quantify mitochondrial mass).

To follow the suggestion of the reviewer, we added an additional assay relying on the quantification of the fluorescence intensity of MitoTracker Green by flow cytometry (new Figure 6G and 8I; subsection 2 Over-expressed AURKA triggers mitophagy of fragmented mitochondria", first paragraph and subsection "The cancer-related AURKA Phe31Ile is more imported into mitochondria and it accelerates mitophagy and ATP production", third paragraph). Given that this probe is insensitive to the polarization status of mitochondria, it gives a direct readout of the mitochondrial mass. MitoTracker Green confirmed the existence of mitochondrial loss when AURKA is overexpressed. As this probe is very common in the field, we hope that the reviewer will be convinced by the fact that AURKA triggers mitophagy when overexpressed. We also added further experimental evidence showing that cells treated with the autophagy inhibitors 3-methyladenine and Bafilomycin A1 block mitophagy in cells overexpressing AURKA (new Figure 7C; subsection "Over-expressed AURKA triggers mitophagy of fragmented mitochondria", second paragraph). Overall, we hope that the reviewer will be reassured that AURKA induces mitophagy when overexpressed.

> Based on these and many other issues with the paper, I cannot support publication in eLife. I think a much more rigorous analysis would need to be done. Moreover, if AURKA is functioning as a kinase in the mitochondria, what are its substrates and how does phosphorylation by AURKA alter their functions.

Although we obtained a proteomic analysis of the AURKA interactome, we agree with the reviewer that key mitochondrial substrates of AURKA need to be functionally validated. However, we feel that this will be the focus of future work, and it falls out of the scopes of the present manuscript.

We hope that our answers and additional experiments provided will reconcile the reviewer with our work and convince him/her of its validity.

> Reviewer \#3:
>
> \[...\] In general, the data showing mitochondrial localization of Aurora A are solid and highly interesting and it is also clear that AurkA overexpression induces significant morphological and functional changes in mitochondria. Major remaining question is whether these changes are a consequence of the a) AurkA-NML1 interaction, b) the established RALA-DNML1-dependent pathway that controls mitochondrial fission/fusion or c) a fusion/fission-independent pathway as suggested by the Phe31Ile mutant. Some of these questions are acknowledged in the Discussion but it seems that the information in the manuscript remains a bit preliminary until some of these questions are addressed more in detail.

We thank reviewer \#3 for their thoughtful comments on our manuscript. We feel that their suggestions greatly improved the overall quality of our study in this present version.

> 1\) The localization of AurA seems to be variable in the different images shown. For instance is only cytoplasmic in Figure 1 (or Figure 2D) with certain spotted (mitochondria) pattern, but is both cytoplasmic and nuclear in Figure 2B, C with no evidences of spotted (mitochondrial pattern). One possibility is that cell in Figure 1 is G1 whereas it might be S/G2 in Figure 2. The authors should clarify the pattern of Aurora A localization (and co-localization with mitochondria) in the different cell cycle stages.

We thank the reviewer for this comment. The differential localisation is most likely due to the expression levels. In Figure 1 and 2D, AURKA is expressed under its endogenous promoter, which yields physiological levels of the kinase in the cell. Conversely, in Figure 2B/C the kinase is strongly overexpressed and a stronger labelling in the cytosol is indeed present. That said, we also explored whether endogenous AURKA shuttles to mitochondria in a specific cell cycle phase. Of note, this aspect was also raised by reviewer \#1 (c.f. point 3 of the response to the reviewer \#1). These results were included in the new version of the manuscript (new Figure 1---figure supplement 1A; subsection "AURKA localises in the mitochondrial matrix via an N-terminal MTS and it undergoes a double proteolytic cleavage", first paragraph), and show that AURKA shuttles to mitochondria in any cell cycle phase and regardless to its abundance. We hope that the reviewer will be satisfied with this new finding.

This cytosolic staining shows AURKA before its import into mitochondria, but also the mitochondrial form exported from the organelles. These two forms, which can be distinguished on Western blotting as shown in Figure 2A, are indistinguishable on immunofluorescent micrographs.

> 2\) It is somehow surprising that OCR does not change after Aurora A knockdown. I wonder whether the knockdown levels are not sufficient. The authors should also use AurkA inhibitors to test mitochondrial activity (Seahorse).

We thank the reviewer for this comment, which allowed us to go further in our understanding of the mitochondrial changes induced by AURKA. Following their suggestion, we explored OCR in cells treated with an acute (250 nm, 10 min) or prolonged (100 nM, 3 h) dose of MLN8237, and we did not observe OCR variations in any of the conditions analysed (new Figure 3L; subsection "Over-expressed AURKA increases the abundance of mitochondrial complex IV and up-regulates ATP production", second paragraph). This is in agreement with the similar effect of *AURKA* gene silencing on mitochondrial respiration (Figure 3H; see the aforementioned paragraph). Although MLN8237 induces mitochondrial elongation in four carcinoma cell lines routinely used for cancer cell biology (new Figure 5B; subsection "AURKA regulates mitochondrial fusion when over-expressed", third paragraph), an elongation morphologically comparable is observed in cells overexpressing AURKA. In the case of overexpressed AURKA a positive selection of mitochondria (through mitophagy and fusion) enhances mitochondrial ATP production. Instead, at physiological levels, AURKA promotes mitochondrial fragmentation as revealed by an increased mitochondrial interconnectivity when AURKA is silenced or inhibited. Under these conditions, there is no positive mitochondrial selection and thus no increase in ATP production is required. This is now more clearly stated in the manuscript, subsection "AURKA regulates mitochondrial morphology", first paragraph. We hope that the reviewer will be satisfied with these new findings and will agree on the fact that they further help the understanding of the roles of AURKA into mitochondria.

> 3\) On a related issue, how did the authors manage to prevent secondary consequences of cell cycle arrest/defects in these assays? Does changes in mitochondria induced by AurkA occur in parallel to changes in cell cycle phases (entry into G2 etc.)?

Following up on the new results described in the first point, AURKA localises to mitochondria in all cell cycle phases (Figure 1---figure supplement 1A; subsection "AURKA localises in the mitochondrial matrix via an N-terminal MTS and it undergoes a double 85 proteolytic cleavage", first paragraph). This supports the fact that its activity into mitochondria is constant throughout the cell cycle, and not only at cell cycle checkpoints.

> 4\) It is not clear whether the authors are proposing a direct activity of Aurora A on DNML1-Ser637? Or changes in Ser 637 are RALA-dependent following the already established pathway? A direct interaction between AurkA and DNML1 is suggested by the proteomics data but the authors do not evaluate this functionally. One would assume that is a RALA-dependent process but his has not been tested and RALA apparently was not present in these complexes. This mechanism should be analyzed in detail and properly clarified. Perhaps rescue assays with RalA, DNML1 would help.

Again, we thank the reviewer for this comment, which helped us in showing that AURKA acts on two different pathways: (1) AURKA phosphorylates RALA to trigger its mitochondrial localisation (RALA-dependent pathway, described in Kashatus et al., 2011); (2) AURKA enters mitochondria in a RALA-independent pathway. First, RALA is not required for the import of AURKA inside mitochondria (new Figure 1---figure supplement 3E; subsection "AURKA localises in the mitochondrial matrix via an N-terminal MTS and it undergoes a double proteolytic cleavage", fourth paragraph), according to our new data. Second, a version of AURKA (AURKA ΔNter) which can phosphorylate RALA on Ser194 (Figure 3---figure supplement 6D; subsection "AURKA regulates mitochondrial fission in physiological conditions", first paragraph), but is not importable into mitochondria, was not capable of reverting the mitochondrial connectivity phenotype observed when endogenous AURKA is depleted by siRNA (new Figure 3---figure supplement 6C; see the aforementioned paragraph). This demonstrated that it is the presence and the function of AURKA into mitochondria that are required to maintain mitochondrial morphology. We included these data in the new version of the manuscript, and we hope that these findings will satisfy the reviewer. Additional FRET data not included in the manuscript showed that the physical interaction between AURKA and DNM1L does not depend on the presence of RALA, as it is retrieved in cells treated with a control- or with a RALA-specific siRNA. We attach these results in [Author response Image 2](#respfig2){ref-type="fig"}.

![Fluorescence lifetime quantification of MCF7 cells transfected with AURKA-GFP and an empty vector (-) or DNM1L-mCherry, and silenced or not for RALA.\
\*\*\* P\<0.001; NS: not significant.](elife-38111-resp-fig2){#respfig2}

We found that the fission-prone function of AURKA expressed at physiological levels (RALA-independent pathway) goes through the phosphorylation of DNM1L on Ser637 (Figure 3---figure supplement 6B; subsection "AURKA regulates mitochondrial fission in physiological conditions", first paragraph), as indicated in the first version of our manuscript. Conversely, the RALA-dependent pathways relies on the phosphorylation of DNM1L on Ser616 (Kashatus et al., 2011). Therefore, data provided on the phosphorylation status of DNM1L further support the existence of two distinct pathways. We hope that the existence of a RALA-dependent and -independent pathway for the functions of AURKA at mitochondria will satisfy the reviewer.

> 5\) Data with the Phe31Ile mutant are quite interesting and this mutant has a significant effect in mitophagy and mitochondrial activity. However, given the lack of specific mechanism as discussed in the previous point, it is not completely clear why this mutant induces these effects. The authors indicate that the mutations favors entry into the mitochondria; however, no changes in interconnectivity are shown. As mitophagy was previously proposed to be triggered or favored by these changes in connectivity, the actual reason for the phenotype induced by the AurkA mutant is not really clear. In addition, these data actually argue against the DNML1-fusion mechanism proposed in the earlier figures in the manuscript.

As explained in the previous point, we now show that the role of AURKA into mitochondrial falls out of its interaction with RALA. Therefore, the reason why AURKA Phe31Ile has an even more drastic effect on mitophagy and energy production than normal AURKA must be searched into the intrinsic characteristics of the mutant. By molecular modelling, we show that the MTS adopts a different conformation when Phe31 is mutated into an Ala. This change makes AURKA more suitable to enter mitochondria.

As the reviewer observes, it is true that there are no differences in terms of mitochondrial connectivity between normal and mutated AURKA. The new findings inserted in the paper (new Figure 3L and 5B; subsection "Over-expressed AURKA increases the abundance of mitochondrial complex IV and up-regulates ATP production", second paragraph and subsection "AURKA regulates mitochondrial fusion when over-expressed", third paragraph) now underline that the connectivity is a poor readout to estimate the energetic capabilities of the mitochondrial network in the paradigm of AURKA. Indeed, AURKA Phe31Ile enhances mitophagy and energy production more importantly than normal AURKA, although the mitochondrial connectivity degree is comparable. Future studies will certainly elucidate the complex scenario of the AURKA F31I interactome, but this is not the focus of the present manuscript.

\[Editors\' note: the author responses to the re-review follow.\]

> On the whole, there was consensus that the paper was much improved. However, some remaining issues were identified that need to be addressed before acceptance, as outlined below:
>
> All three reviewers found the data on mitophagy not particularly convincing. There was also concern that the cancer data was not as well-developed as it might be with respect to rescuing the mutation and imaging. Therefore, we suggest that you also omit this part of the story unless you feel that it can be better supported. These are our only requests required for acceptance. I include the comments of the reviewers below only for your own reference and feedback.

First, we would like to thank the three reviewers and the reviewing editor for their constructive comments, and for helping us to see our manuscript from another perspective.

There was only one request by the editors for the acceptance of the paper: removing the parts concerning mitophagy and the cancer-related mutation of AURKA Phe31Ile.

For this version of the manuscript, we followed the editorial requests and removed the sections concerning mitophagy and the cancer-related AURKA polymorphism Phe31Ile.
